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Introduction 
 The siddha system of medicine is the most ancient system of medicine that 
originated along   with the origin of plants. The main ingredient in siddha system is 
the herbs of medicinal value. Late it redefined by the “siddhars”,they blessed 
people. 
Siddha gains its importance by treating the cause of the diseases and not 
merely the symptoms.The system deals with tridosha theory and panchapootha 
theory regarding the assessment and treatment of the disease. 
 Balavagadam is the branch of medical science of siddhars which deals with 
the diseases of children,their essential nature,especially on the functional changes 
together with planetary influences,morbid diathesis etc.., and the treatment. 
In balavagadam the diseases are broadly classified into agakkarananoikal and 
purakaarananoikal. 
 The concept of  balavaagadam  in the siddha literature is in conformity with 
the fact that the nature of the tridhosham in the constitution of the parents at the 
time of giving birth of a child also produces similar dhoshams in the constitution 
of the child. 
  ‘gpwe;jehs; gps;isf;FjhNded;wha; 
  gpjthNygpzpAlypd; NkNyNjhd;Wk;’ 
 
‘nfhy;Yfpd;w fzNkjf; fuq;fNsJ 
$Wkpit #upnad;w FowNyJ 
Gy;Yfpd;w jhaNy je;ijahNy 
Gidf;nfhb glu;e;jJNghy; glu;e;jJ ,g;ghy;’ 
-ghythflk; (gf;fk; vz;- 6) 
 The above lines stated that certain diseases are caused by parents to the 
children. The recent studies in the modern world ensure it.The recent researches 
evidences that the mother’s dietary changes can affect the fetus microbiome and 
also it encoded in DNA. It affects child’s growth and development of immune 
system. By this way the children get inherited diseases. This may be the reason for 
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agakaarananooikal. Purakaarananoikal may be caused by any pathogens from the 
surroundings or any other factors from environment.  
 
 
Suram 
“Dis harmony is the cause of disease and therefore re -establishment of 
harmony is the cure” which is the proverb of our ancient system of siddha 
medicine. Siddha treatises describe disease in man do not originate in himself 
alone, but also from the environmental influences which act upon him. 
Our literature supports the fact that suram is established when we go wrong with 
the nature, in food, Lifestyle, behavior,emotions, etc.., internally along with the 
external environment. 
Hence siddha text suggests suram under noinilai, and not merely a symptom.so 
suram may be comparable with fever and its symptoms. Fever in children is one 
of the most common manifestations of an illness which makes the parents seek 
medical attention early. Fever can be defined as a regulated elevation in body 
temperature above the customary set point of the hypothalamic  thermostat. 
Siddha system of medicine which has an indigenous effect in clearing the root 
cause of the disease will be unique in clearing suram. Hence I hope the trial drug 
“vettumarankuligai” will be effective in curing suram. 
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AIMS AND OBJECTIVES 
Suram may be due to body immune response (or) it can be the 
presenting feature of serious (or) life threatening disease, hence it develops an 
importance in clinical approach to the patients in order to distinguish the mild 
benign illness from those potentially more serious. 
Aim 
To evaluate the clinical efficacy of the drug “vettumaran kuligai” to 
reduce increased temperature,and its presentations like heat,head 
ache,chills,muscle pain,malaise etc.,, 
Objectives 
1. To collect and review the ideas mentioned in the ancient siddha 
literature about the  disease. 
2. To study the disease suram on the basis of mukkutram udalthathukkal,  
 kaalangal,neerkuri,neikuri,age, sex and economic status 
3. To use the modern parameters in the investigations of the disease that   
enhances to observe the progress of the patient. 
 4.  To have clinical trial on “vettumaran kuligai” 
 5.  To evaluate the pharmacological study of the trial drug 
 6.  To study the biochemical analysis the trial drug 
 7.  To study the acute toxicity study of the trial drug 
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
Ruk; 
capudy; jd;dpiy tpl;L khwp Gwepiyfspy; guTjy; ‘Ruk;’ 
vdg;gLfpwJ 
capudy ;  
];Jhy #l;rk gQ;rG+jkakhd cly>; capH NrHe;jpUf;fg;gl;lj; 
Njfj;ij  ed;dpiyapy; itj;jpUf;fg;gl;l moy;> capudy; (m) 
capuf;fpdp vdg;gLk;. 
Neha; ,ay;G 
 Flypy; rPjk; mjpfkhfp clypd; ,aw;if R+L jd;dsTf;F kpQ;rp 
vOe;J fz;nzupjy;> tha; Fkl;ly;> cly; Nehjy;> the;jpahjy; Kjypa gy 
FwpFzq;fisj; Njhw;Wtpf;Fk;. 
Neha;fSf;nfy;yhk; murd ; 
  ‘nrhy;yNt Ruj;jpDl jpwik Nfsha; 
   rlj;jpYs;s gpzpf;nfy;yh kpuhrhthFk; 
  nay;yNt ekDf;F nkhf;F nkhf;Fk;.....” 
        -ruNge;jpuH Ehy; 
Ruk; cyfpYs;s Neha;fs; vy;yhtw;wpw;Fk; murd; Nghd;wjhFk;. 
Ruk; vkDf;F epfuhdJ vd;W ruNge;jpuH Ehy; $WfpwJ. 
Ruk; tuyhW 
  ‘js;sNt jf;fdpl Nts;tpidjhd; 
   rhk;grptd; Nfhgj;jhy; mopj;jNghJ 
  ney;yNt new;wpf;fz; Rthiy jd;dpy; 
   Neuhf Gwg;gl;L Neu;e;jjhNk’ 
        -ruNge;jpuH Ehy; 17 - 18 
 Ruk; rptdpd; Nfhgj;jpw;F ,izahdJ. jd;Dila ahfj;ij 
mopj;j NghJ gukrptdpd; %d;whk; fz;zpy; ,Ue;J cz;lhd 
Rthiyapy; ,Ue;J Vw;gl;lJ> vd;W Ruj;jpd; tuyhW gw;wp ruNge;jpuH jhd; 
,aw;wpa Ru Nuhf rpfpr;ir vd;Dk; Ehypy; $wpAs;shH. 
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NtWngau;fs; 
  ‘ntk;ik ntg;G ntWf;Fq; fha;r;ry; 
Jk;kh fhq;if #L joydy; 
Rk;ik gpwg;gpwg;gpy; njhlH Neha; 
gk;ky; Neha; fhe;jy; gy ngau;RuNk’ 
- rpj;jkUj;Jtk; (nghJ) 
Ruj;jpw;F> 
 ntk;ik  
 ntg;G 
 fhe;jy; 
 fhq;if 
 fha;r;ry; 
 #L 
 mdy; 
 gpwg;gpy; ,wg;gpy; njhlUk; Neha; 
 gk;ky; Neha; 
vdg; gy NtW ngaHfs; cz;L. 
Neha; tUk; top 
 nghq;fpnaO kjiyaH NrU RukhdJ <uQ;nrOj;j thW 
nghUkpnaO kd;dkjpdhYU gldj;jpdhy; fizapdhy; 
khe;jkjpdhy; 
;  jq;fpnaOk; fpUkpahy; ,iw Nfhgj;jpdhy; jiuahy; FspupdhYk; 
jg;ghkNy ePupd; Njhrkjpdhypdp jiyjdpy; tprk; nfhz;ljhy; 
kq;F ntapy; fhq;ifahy; jPapDlntf;ifahy; ghypDl 
Njhrkjpdhy; gfuj;jp k[;i[Ak; mdNywp ,uj;jNk #Nlwp RukJ 
cz;lhFk;. 
-Fk;gKdp ghythflk;. 
ghyu;fSf;F fPo;f;fz;l fhuzq;fspdhy; Ruk; cz;lhfpwJ vd 
Fk;gKdp ghythflk; FwpgpLfpwJ. 
 <uk; 
 cztpd; Njhlk; 
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 fiz 
 khe;jk; 
 clypy; jq;Fk; fpUkp 
 ,iw Nfhgk; 
 Fspu;e;j jiu 
 Fspu;r;rp 
 ePupd; Njhlk; 
 jiyapdpy; tplk; NrUjy; 
 ghypd; Njhlk; 
,j;jifa fhuzq;fshy; cz;lhd Ngjq;fspdhy; vd;G> k[;i[ 
,tw;wpy; mdy; Vwp #liltjhy; Foe;ijfSf;F Ruk; cz;lhfpwJ. 
ghyu; Ru epjhdk; 
 ‘fhg;ghd tuyhW nrhy;yf;NfS 
  fdj;j tapWjdpy; ke;jq;fs; fyj;jyhYk; 
 jhg;ghd c\;zq;fs; kpFe;jjhYk; 
  jiytyp tprKk; fz;Njh\k; Nru;e;jjdhYk; 
 Mg;ghd m];jpNahL <uy; k[;i[ 
  moNywp tp\Nkwp njhe;jk; nfhz;L   
Neg;ghd ghyu; Ruk; vl;Lf;Fk; jhd; 
 epr;rakha; ngau;fs; tif epfo;j;JtNd. 
- kjiy Neha; njhFjp-1 
tapw;wpy; ke;jk; Nru;tjhYk;> c\;zk; kpFtjhYk;> jiytyp> eQ;R 
fz;Njhlk; Mfpad Nru;tjhYk; moyhdJ kpFe;J er;R 
jd;ikNahL njhe;jk; nfhs;tjhy; Foe;ijfSf;F vl;L tifahd 
Ruq;fs; cz;lhtjhf kjiy Neha; njhFjp Ehypy; 
Fwpg;gplg;gl;Ls;sJ. 
gps;isg; gpzp kUj;Jtk; Ehypy ;> 
 cztpd; NtWghLfs; 
 khe;jk; 
 gy tifg;gl;l eQ;R 
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 vz;nza; Nja;j;J Fspj;j gpwF Iak; kpFe;j nhUl;fis 
cl;nfhs;Sjy; 
 Fspu;e;j ePiu gUFjy; 
 fhak; gLjy; 
 nghup kh> gok;> fgpy thio jpd;dy; 
 fpUkp ,Uj;jy; 
Kjypa fhuzq;fshy; Foe;ijfSf;F Ruk; cz;lhtjhf 
kU>m.Re;juuhrd; mtu;fs; Fwpg;gpLfpwhH. 
Neha; vz;: 
 ghythfl Ehypy; Ruk; tif 20 vdf; $wg;gl;Ls;sJ. 
mit> 
1. thj Ruk; - Cidg; gw;wp tUk;. 
2. gpj;j Ruk; - Njhiyg; gw;wp tUk; 
3. Ia Ruk; - vd;ig rhu;e;J cliy ntJg;gp tUj;Jk; 
4. kPshj Ia Ruk; 
 tplhj Ruk; fha;jy; (m) tpl;L tpl;L Ruk; fha;jy; 
 eh twl;rp 
 the;jp 
 cly; typ 
Kjypa FwpFzq;fs; fhZk;. 
5. khe;j Ruk; 
 tplh Ruk; 
 clw;fl;Lfs; gyk; Fiwe;J fhZk; 
6. fopr;ry; Ruk; 
 kpff; fha;r;ry; 
 tapW ,iue;J gy epwkhf fopjy; 
 cztpy; tpUg;gkpd;ik 
 if fhy; cjwy; fhZk; 
7. Mk Ruk; 
 rhkj;jpw;F xUKiw #L mjpfkhf fhZk; 
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 ePu; Ntl;if 
 cly; ,isj;Jf; fhZk; 
 jha;g;ghy; cz;z KbahJ. 
8. rPj Ruk; 
 Iak; kpFjpg; gLtjhy; tUk; 
 Ruk; fhAk; 
9. Fspu; Ruk; 
 Kjypy; Fspu; cz;lhfpg; gpd; Ruk; cz;lhFk; 
 cly; NehFk; 
 eik cz;lhFk; 
10. er;R Ruk; 
 Gw tPr;R 
 tpf;fy; 
 Ruk; fhZk; 
11. tplh Ruk; 
 tplhJ Ruk; fhAk; 
 ePu;Ntl;if 
 cly; vupT 
 kyr;rpf;fy; 
12. khwy; Ruk; 
 Ruk; xU ehs; tpl;L xU ehs; tUk; 
 Njhs; NehFk; 
 fy;yPuy; kz;zPuy; tsu;r;rp fhZk; 
13. fz Ruk; 
 nfhg;G+o;> EiuaPuy; Gz;zhFk; 
 kaf;fk; cz;lhFk; 
14. cl;fha;r;ry; 
 ePu; Fiwe;J ,opAk; 
 khu;gpy; kl;Lk; Ruk; fhZk; 
 kyk; NghFk; NghJ Mrd thapy; vupr;ry; fhZk; 
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15. FUjp Ruk; 
 FUjpiag; gw;wp tUk; 
 jiy Rw;Wk; 
 if> fhy;fspy; Ntu;it jz;zPuha; xOFk; 
16. Cd; Ruk; 
 mdy; Nghy; Ruk; fhAk; 
 cly; ntSf;Fk; 
 FUjp FiwAk; 
17. mj;jp Ruk; 
 Ruk; rhkk; NjhWk; mjpfg;gLk; 
 the;jp fhZk; 
 rpW ePu; rptf;Fk; 
 NrhifAld; ,Uky; fhZk; 
18. jhg Ruk; 
 cly; vupAk; 
 Nky; %r;R 
 eh twl;rp 
19. clk;G Neha;f; fha;r;ry; 
 cly; NehFk; 
 fz;fs; el;l fz;fshfNt ,Uf;Fk; 
 ghYz;zhJ 
20. md;gdhjp Ruk; 
 cly; ntJk;Gjy; 
 fz; rptj;jy; 
 vijg; ghu;j;jhYk; gak; 
 kyr;rpf;fy; Mfpad fhZk; 
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NtW kUj;Jt Ehy;fspy; Ruk; tiffs;> 
vz; Ehypd; ngau; Neha; 
1 
gps;isg;gpzp kUj;Jtk; - 
kU.m.Re;juuhrd; 
32 
2 kjiy Neha; njhFjp I - kU.T.Nkhfd;uh[; 08 
3 rPtul;rhkpu;jk; 23 
4 jd;te;j;up itj;jpak; gFjp II  64 
5 Fk;gKdp ghythflk; 10 
 
Fk;gKdp ghythflk; 
‘rPupYW jhupyF fhupioNa Nfspdp Rutif <uQ;RJk; 
NrU FUNthJ Kiw Kd;Dhypd;gb rpwg;ghawpe;j tz;zk; 
NeUwNthbdp thjRukhdJk; gpj;jNkhL Nru;g;gRuk; 
newpNkT jpupNjhrk; cs;RukhfNt md;ghdjp Ruk;jhd; 
ghupdpa nuj;jRu kj;jpapd; RukJk; khq;fprk; khe;jRuKk; 
gfUkpit<uQ;RJk; MfkjpNyAWk; ghyUlyhfKwNt 
NgupYW FzkJk; gupfhukhdJk; NgRNtndht; nthd;wpdp 
NgjKwhky; Fk;gKdp aUshy; gpd;dhywpe;J ghNu’ 
   Ruk; gj;J tifg;gLk;. mit> 
thj Ruk; cs; Ruk; 
gpj;j Ruk; ,uj;j Ruk; 
Nrj;Jk Ruk; mj;jp Ruk; 
jpupNjhr Ruk; khq;fp\ Ruk; 
md;gdhjp Ruk; khe;j Ruk; 
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NkYk; Mj;kul;rhkpu;j Ehypy;> 
 ‘ciuj;NjhNk ghyUf;F Ru tFg;G 
  cly; fhAk; Mk Ruk; cWjpnkj;j 
 epiwj;jnjhU uj;j Ruk; md;gdhjp Ruk; 
  Neuhd khq;fp\ RuKkhFk; 
 jpiuj;JNk mj;jpRuk; thj gpj;jQ; 
  rpNyw;gdj;J Runkd;W nrg;gyhFk; 
 kiwj;jnjhU khe;jRu kl;rue;jhd; 
  kfhNjh\ khe;jRu nkd;dyhNk 
 MNkjh dpuj;jfz RuK khFk; 
  miwe;j fzf; fha;r;ryhFk; Fspu;RuK khe;jk; 
 jhNkjhd; khwy;rpq; fha;r;ryhFk; 
  rhu;thd goQ;RuKk; rPjRu KkhFk; 
 fhNkjhd; mjprhu RuKkhFk; 
  fowpdhu; the;jpRuk; tpf;fy; jhfk; 
 ehNkjhd; RutFg;G nrhd;Ndhkg;gh 
  etpd;wpl;lhu; Fk;gKdp etpd;wpl;lhNu’ 
vd;W ghyu;fSf;F cz;lhFk; Ruk; tifg;gLj;jg;gl;Ls;sJ. 
 
Ruk; Nehapy; fhZk; FwpFzq;fs ; 
 cly; #lhf ,Uj;jy; 
 jiy fdj;jy; 
 fz; vupr;ry; 
 jiy typ 
 eh twl;rp 
 ehtpy; kh gbe;J fhhzy; 
 khu;G typ 
 rspf;fl;L 
 ,Uky; 
 Jk;ky; 
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 %f;FePu; gha;jy; 
 tapw;wpy; typ 
 the;jp 
 rpWePu; kQ;rspj;J ,wq;fy; 
 ePu;f;fLg;G 
 ePu;kyk; Nghjy; 
 Fuy; fk;ky; 
 tha;f;ifj;jy; 
 grpapd;ik 
 cly; ,isj;jy; 
Kjypa FwpFzq;fspy; jhJ Njhl NtWghLfSf;fpzq;fTk;> 
Ruj;jpd; gpupTfSf;Fj; jFe;jgbAk; rpy (m) gy FwpFzq;fs; Ru 
Nehapy; Njhd;Wk;. 
,itad;wp> 
 cz;Zk; cztpy; tpUg;gkpd;ik 
 cly; epwk; khwy; 
 cly; fdkhapUj;jy; 
 kaf;fk; 
 nfhl;lhtp 
 ,utpy; Jhf;fkpd;ik 
 vg;nghUs; gl;lhYk; cly; $ry; 
 eh Ritawpahik 
 fz;fspy; ePu; tbjy; 
KjypadTk; Ruj;jpy; Njhd;Wk; FwpFzq;fshfg; gps;isg; gpzp 
kUj;Jt Ehy; $WfpwJ. 
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Kf;Fw;wtpay; 
 ‘cw;wNjhu; clypd; $W  
  cWg;Gld; tputp epd;W 
 Kw;WNk Neha;fs; vy;yhk; 
  Kjy;jdpy; Njhd;Wk;NghJ 
 gw;WNk thj gpj;j 
  rpNyw;gde; jd;dpy; xd;iwg; 
 gw;wpNa Njhd;W nkd;W 
  gfu;e;jdu; Kdptu;jhNk 
- mfj;jpau; FUehb 
clypy; Neha;fs; gpwg;gjw;fhd topfs; gythf ,Ug;gpDk; mit 
Njhd;Wk; NghJ thjk;> gpj;jk;> fgk; Mfpa Kf;Fw;wq;fspy; VNjDk; 
xd;iwg; gw;wpNa tUk; vd mfj;jpau; Ehy; $WfpwJ. mJNghy; 
Ruj;jpYk; Kjypy; Kf;Fw;wq;fspy; fgk; ghjpg;gile;J> gpd; kw;w 
Fw;wq;fSk; ghjpg;gilfpd;wd. 
 ‘ke;jk; tuhNj RuKk; tuhNj Ruk; te;jhy; 
  ke;j kwhNj rPjkwhNj...’ 
      -ghyNuhf epjhdk;- guuhrNrfuk; 
  ‘Fly; jd;dpy; rPjkyhJ RuKk; tuhJ” 
vDk; Njud; $w;wpy; ,Ue;J RuNeha; Njhd;Wtjw;F Kjd;ikf; 
fhuzk; Fly; kw;Wk; ,iug;igapy; ngUFk; ‘rPjNk’ MFk; vd;gjid 
mwpayhk;. RuNeha; tUtjw;F Kjd;Kjypy; ,iug;igapy; rPjk; ngUfp 
Neha; cw;whu;f;Fk; Neha; jPu;g;ghu;f;Fk; mjid mwpAk;gb nra;tjhy; ,J 
‘Ruk;’ vdg; ngau; ngw;wJ. 
gjpnzz; rpj;ju; ehb Ehy;gb> 
 ‘tFj;j Kiwg;ghL ke;jj;jhy; thAthk; 
 kpFe;jdy; thAthy; tpise;jpLk; NehNaahk; 
 gFj;jpit ,uz;lhy; ghur; RuKWk;  
 Kfj;jpit %d;whd; Kj;Njh\k; fhZNk’ 
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ke;jk; cz;lhdhy; thA kpFk;. kpFe;j thAtpdhy; mdy; cz;lhFk;. ,e;j 
thATk; mdYk; ,uz;LNk Ruj;jpw;F fhuzq;fshFk;. ke;jk;> thA> mdy; 
%d;Wk; $bdhy; Kj;Njh\k; cz;lhFk;. 
Mkk; cUthFk; tpjk; 
 Ruj;jpw;F Kjd;ikahd fhuzk; ,iug;ig kw;Wk; Fly; ,tw;wpy; 
cz;lhFk; ‘Mkk ;’ MFk;. 
jtwhd czTg; gof;fj;jpdhYk; jfhj eltbf;ifahYk; Fly; 
kw;Wk; ,iug;igapy; mf;dp ke;jk; Vw;gLk; NghJk;> cztpdhy; 
cUthf;fg;gl;l md;durk; rPuhf cUthfhky; ‘Mkk;’ vd;fpd;w 
er;Rj;jd;ikAila fgk; tapw;wpy; cUthfpwJ. 
,t;thW cUthd Mk milahdJ ,iug;igapy; cs;s thjk;> gpj;jk>; 
fgk; Kjypa Njhlq;fspy; VNjDk; xd;W jdpj;J (m) ,uz;L Fw;wq;fshf 
Nru;e;Njh jq;fshy; ,ad;w kl;Lk; ,sf;fp cg;gr;nra;fpd;wd. 
,g;gb ,sfp ngUj;j milahdJ capudiy ntspg;gLj;jp> 
rluhf;fpdpiaf; Fiwj;J clw;F td;ikj; juf;$ba czTfis rupahf 
nrupf;fnthl;lhky; nra;fpwJ. ,e;j nrupahj czT Fok;Gfs; urj;ij 
nrYj;Jfpd;w ehsq;fisAk; kw;WKs;s kapu;JisfisAk; milj;J> 
tpau;tpaid Fiwj;JtpLfpwJ. 
mjd;gpd; mf;Fok;Gfs; gf;Fthraj;jpy; ,aw;ifaha; cs;s clw;wPia 
tprpwp NknyOg;gp> cly; Kw;Wk; mt;tdiy gutr;nra;fpwJ. ,t;thW 
fjpj;J vOe;j mdy; ‘Ruk;’ vdg;gLfpwJ. ,e;j RukhdJ tsp> moy;> Iak; 
Mfpa Fw;wq;fspd; khWjy;> td;ik ,tw;wpw;F Vw;g ntspj;Njhw;wk; 
milfpwJ. 
,t;thW ,iug;igapy; cz;lhFk; Nfl;bdhy; VO clw; jhJf;fSk; kw;Wk; 
ePu; vU ,itAk; Nflilfpd;wd. 
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Mfhu tpfhuk; 
Mkhraj;jpy; ke;jk; 
Mkk; 
Kj;Njhlk; xd;W (m) ,uz;L (m) %d;Wk; 
tpau;it ehsk; 
milg;G 
gf;Fthraj;jpy; 
capudy; rluhf;fpdp 
tpau;it FiwT grpapd;ik 
cly; Kw;Wk; capudy; 
guTjy; 
Ruk; 
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ehb eil 
 ‘cWjpAs;s gpj;jkJ Njhd;wpy; ntg;G  
  c\;z thA mj;jpRu kjprhuq;fs;  
 kwjpAld; fpWfpWg;G igj;jpa Nuhfk; 
  tsu;Nrhif aonyupT fhe;jy; ifg;G’ 
- rjfehb 
gpj;j ehb jdpj;J kPwp elf;fpd; Ruk; FwpFzq;fs; fhZk;. NkYk;> 
 ‘thj Nrj;Jk njhe;j ehb 
 gpj;j Ia njhe;j ehb 
 gpj;j thj njhe;j ehb  
 tiffspYk; Ruk; kw;Wk; mtw;wpd; tiffshd mj;jp Ruk;> 
Kiwf;fha;r;ry; Kjypa Neha;fs; Njhd;Wk; vd ehb Ehy;fspy; 
$wg;gl;Ls;sJ. 
Kf;Fw;w NtWghL 
rpj;j kUj;Jt Kiwg;gb kdpj clyhdJ 96 jj;Jtq;fshy; Mf;fg;gl;lJ. 
,e;j jj;Jtq;fspy; VNjDk; khw;wk; Vw;gLkhdhy; Neha; Vw;gLk;. Kjy; 
khw;wkhdJ gQ;rG+j mbg;gilapy; Vw;gl;L gpd; Kf;Fw;wkhfpa thjk; 
gpj;jk; fgk; ghjpg;gilAk;. ,t;thW cz;lhd ghjpg;ghdJ cly; jhJf;fs; 
kw;Wk; kyq;fspd; thapyhf ntspg;gLk;. 
 ‘kpfpDk; FiwapDk; Neha; nra;Ak; EhNyhu; 
   tsp Kjyh naz;zpa %d;W’ 
- jpUf;Fws;> kUe;J mjpfhuk;. 
 
Ruk; Nehapy; Kf;Fw;wq;fspd; epiy 
thjk; 
gilf;Fk; jd;ikf; nfhz;l thjj;jpd; Fzq;fs; nefpo;r;rp> guTjy;> 
twl;rp> tpiuthf ,lk; tpl;L ,lk; Nghjy>; Fspu;r;rp>kpf Ez;zpajha; 
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,Uj;jy;> vd;gjhFk;. thjk; ghjpf;fg;gbd; ,tw;wpd; Fzq;fs; kpFe;Njh 
Fiwe;Njh fhZk;. 
 gpuhzd; - Ruk>; %r;R tpl rpukk; cz;lhFk; 
 mghdd; - rpWePu; FiwT> kyr;rpf;fy; (m) fopr;ry; 
cz;lhFk; 
 tpahdd; - cly; typ> cly; KOtJk; ntg;gk; guty; 
 cjhdd; - cly; td;ik FiwT> Fuy; fk;ky; fhZk; 
 rkhdd; - grpf;FiwT cz;lhFk; 
 ehfd; - fz; epw khWghL 
 $u;kd; - fz;zpy; ePu; tbjy; 
 fpUfud; - eh twl;rp> Jk;ky;> ,Uky; cz;lhFk; 
 Njtjj;jd; - Jhf;fkpd;ik 
 jdQ;rad; -  
 
gpj;jk; 
 cliyf; fhf;Fk; jd;ikAila moypd; Fzq;fs; ntJg;Gjy;> 
Ez;zpa jd;ik> ePu; jd;ik> nea;g;G> #L cz;lhf;Fjy;> guTjy; 
Mfpadthk;. czT nrupkdk;> ntk;ik> grp> ePu;Ntl;if> Rit> mwpT 
,tw;wpd; cUthf;fj;jpw;F Jizg; GuptJ gpj;jkhFk; 
 mdw;gpj;jk; - grpapd;ik cz;lhFk; 
 ,uQ;rfk; - ,ay;G 
 rhjfk; - cly; Nrhu;T> kd Nrhu;T cz;lhFk; 
 gpuhrfk; - clypy; ntg;gk; fhZk; 
 MNyhrfk; - fz;zpy; ePu; tbjy; fhZk; 
fgk; 
 clypy; cs;s fopTfis ntspNaw;wp cliy ed;dpiyapy; 
itj;J ,Uf;f cjTk; fgj;jhJtpd; Fzq;fs; nea;g;G> ke;jk;> tOtOg;G> 
jpz;ik Mfpadthk;. grp> ePu;Ntl;if> Jauk;> fyf;fk;> ntg;gk; ,tw;iwg; 
nghWj;Jf; nfhs;Sjy;> nea;g;G Kjypad fgj;jpd; ,aw;if gz;Gfs; 
MFk;. 
24 
 
 mtyk;gfk; - Ruj;jjpy; %r;R tpl rpukk; fhzg;gLk;. 
 fpNyjfk; - czT nrupahik> ke;jk; fhZk;. 
 Nghjfk; - eh Ritapd;ik cz;lhFk;. 
 jw;gfk; - fz;zpy; ePu; tbjy;. 
 re;jpfk; - fPy;fspy; typ 
 
gpzpawpKiwik 
clypy; cz;lhFk; Neha;fis nghwp> Gyd;fisf;  nfhz;L fzpj;jy; 
 nghwpahywpjy; 
 Gydhywpjy; 
 tpdhjy; 
nghwpahywpjy; 
nka;  - Njhypy; ntg;gk; fhzy; 
tha;  - eh khT gbe;J fhzy; 
fz;  - nts; top kQ;rspj;J fhzy; 
%f;F  - %f;fpy; ePu; tbjy; 
nrtp  - ,ay;G 
Gydhywpjy; 
CW - Njhy; twl;rp 
Rit - Ritapd;ik 
ghu;it - kq;fpa ghu;it 
kzk; - ,ay;G 
xyp- fhJ ,iur;ry; 
tpdhjy; 
 Nehahspapd; ngau;> taJ> njhopy;> ,lk;> epwk;> FLk;g tuyhW> 
FLk;g #o;epiy> Nehapd; fhyk;> Nehapd; Ke;ija tuyhW> fhy 
khWghLfs; kUj;Jtk; nra;J nfhz;ljw;fhd tuyhW kw;Wk; czT 
Kjypa gof;ftof;fq;fs; gw;wpa jfty;fis Nehahsp my;yJ ngw;Nwhhplk; 
Nfl;L mwpjy.; 
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Ruk; Nehapy; vz;tif Nju;T 
Nehapidf; fzpg;gjw;Fj; JizGupAk; topKiwfis vl;L tiffshf 
rpj;ju;fs; tFj;Js;sdu;. 
mit> 
 ehb 
 ];guprk; 
 eh 
 epwk; 
 nkhop 
 tpop 
 kyk; 
 rpWePu; 
 ‘nka;Fwp njhdp tpop eh ,Ukyk; if;Fwp’ 
- Njiuau; 
  
 
 ‘juzpAs;s tpahjp jd;id al;lhq; fj;jhy; 
   jhdwpa Ntz;LtJ ahNjh ntd;dpy; 
 jpuzpaNjhu; ehb fz;fs; rj;jk; njhL 
   Njfj;jpdJ guprk; tUzk; ehf;F 
 ,uz ky %j;jpukh kpitf nsl;Lk;’ 
- Fzthfl ehb 
ehb eil 
 ek; clypd; Neha; epiyapid fzpg;gjpy; gpujhdkhf 
nrhy;yg;gLtJ ehb eil fzpg;G Kiw MFk;. ehbapd; %yk; 
capu;jhJf;fspd; epiy mwpag;gLfpwJ. 
caph;j;jhJf;fs; Njhd;Wk; tpjk; 
 ,lfiy+ mghdd; = thjk; 
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 gpq;fiy+ gpuhzd;=gpj;jk; 
 ROKid+ rkhdd;=fgk; 
ehbahdJ kzpf;fl;by; ,Ue;J xU tpuy; mq;Fyj;Jf;F fPo; Miu vd;gpd; 
kPJ Ms;fhl;b tpuy;> eL tpuy;> Nkhjpu tpuy; mOj;j czug;gLk;. 
vz;tifj; Nju;Tfspy; ehbNag; gpujhdkhf $wg;gl;L ,Ug;gpDk; 
Foe;ijfSf;F ehb eil rupahf GyG;gLtJ ,y;iy vd kUj;Jt 
Ehy;fspy; Fwpg;gplg;gl;Ls;sJ. 
 ‘mz;blNt jupj;jpuh;fs; tpUj;ju; ghyu; 
  md;ghfj; jz;zPupy; %o;fpNdhu;fs; 
 nfhz;blNt ,tu;fsJ cWg;gpd; jhJ 
  $wNt KbahJ vtu;f;Ff; fpl;Lk; 
 gz;blNt ,g;guPl;ir ahu;jhd; fhz;ghu;’ 
     -Neha; ehly; Neha; Kjy; ehly; jpul;L - 1 
 vdNt Ru Nehapy; Foe;ijfSf;F ehb fzpg;gJ ,ayhj 
xd;whFk;. ed;F tsu;e;j Foe;ijfSf;F kl;LNk ehb fzpf;fKbfpwJ. 
 ];guprk; - Njhypy; ntg;gk;> twl;rp fhzg;gLk;. 
 eh  - eh twl;rp gbe;Jf; fhzy;. 
 epwk;       - eh epwk; ntz;ikahf khgbe;Jf; fhzg;gLk;> fz;fs;             
kQ;rspj;J (m) ntSj;Jf; fhzy; 
 nkhop  - Fuy; fk;ky;> Fuy; xyp jho;e;J fhZk; 
 tpop   - fz;zpy; ePu; tbjy;> kQ;rspj;J (m) ntSj;J fhzy; 
 kyk;  - kyr;rpf;fy; (m) fopr;ry; fhzg;gLk; 
ePu;f;Fwp 
 rpWePu;g; gupNrhjid Kiw ehb eil rupahfg; Gyg;glhj 
epiyfspy; ghjpf;fg;gl;Ls;sf; Fw;wq;fiis mwpag; gad;gLfpwJ. 
rpWePupd; ,ay;Gfs; Ie;J. mit> epwk;> vil> kzk;> Eiu> vQ;ry; 
Mfpadthk;. Ruk; Nehapy; rpWePu; mstpy; Fiwe;Jf; fhzg;gLk;. 
epwk; 
 Ru Nehapy; rpWePu; kQ;rspj;J ntspg;gLk; 
 ‘Rug;gpzp muprdj;Njhaq; fhl;Lk;’ 
- Neha; ehly; Neha; Kjy; ehly; -1 
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nea;f;Fwp 
 ‘gpzpAs;Nshu; ePiuNaw;wg; nghOKk; itj;jg;gpd;du; 
 JzpTW JUk;gp nyz;nza; Njha;j;njhU JspNatpl;lhy; 
 mZfpePu;g; ghk;gpw; fhzpd; mdpyNeha; tl;lkhapd;  
  jzptpyhg; gpj;jNehahe; jq;FKj; ijaNehNa’ 
       -ePu;nea;f;Fwp mWrPu;tpUj;jk; 
ePupy; tpOk; xUj; Jsp vz;nzahdJ  
 ghk;igg; Nghy; ePz;lhy; - thjk; 
 Nkhjpuk; Nghy; fhzg;gl;lhy; - gpj;jk; 
 Kj;Jg; Nghy; mg;gbNa ,Ue;jhy; - fgk; MFk; 
-rpj;j kUj;Jthq;f RUf;fk; 
gUt fhyq;fs; 
fgk; jd;dpiy tsu;r;rpg; ngWk; fhyk;  - gpd;gdpf;fhyk; 
fgk; Ntw;Wepiy tsu;r;rpg; ngWk; fhyk;   - ,sNtdpy;fhyk; 
gpj;jk; jd;dpiy tsu;r;rpg; ngWk; fhyk;  - fhu;fhyk; 
gpj;jk; Ntw;Wepiy tsu;r;rpg; ngWk; fhyk;   - $jpu;fhyk; 
thjk; jd;dpiy tsu;r;rpg; ngWk; fhyk;   - KJNtdpy;fhyk; 
thjk; Ntw;Wepiy tsu;r;rpg; ngWk; fhyk;  - fhu;fhyk; 
epyk; 
 FwpQ;rp> Ky;iy> kUjk;> nea;jy; kw;Wk; ghiy Kjypa ve;j epy 
tifapy; thOk; kf;fSf;Fk; RuNeha; tUk;. Ru Neha; vy;yh Neha;fSf;Fk; 
murd; vdf; $wg;gl;L ,Ug;gjhYk;> jw;Nghijaf; fhyepiy khWghLfs; 
kw;Wk; czT Kiw khWghLfspdhYk; vt;tif epyj;jpdtu;f;Fk; Ruk; 
cz;lhFk;. 
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kUj;Jt topKiw 
 Ruk; cz;lhtjw;F tapw;wpy; cz;lhfpd;w NfhshWfNs 
Kjd;ikaha; epw;Fkhjyhy; mjid Kjypy; ePf;f Ntz;Lk; 
1. Fw;wq;fisj; jd;dpiyg; gLj;j 
 gl;bdp 
 the;jp 
 fopr;ry; 
 ];Ntjdk; nra;ayhk; 
gl;bdp ,Ljy; Ru Neha;f;F rpwg;ghff; $wg;gl;L ,Ug;gpDk; tpUj;ju;> rpW 
Foe;ijfs;>  ruPukpisj;jtu;fSf;Fk;> cly; td;ikaw;wtu;f;Fk; gl;bdpj; 
jPq;if tpistpf;Fk; vd;gjhy;> Foe;ijfSf;Fg; gl;bdp ,Ljy; jtpu;j;jy; 
Ntz;Lk;. 
       -rpj;jkUj;Jthq;f RUf;fk; 
2. ‘rpW czT ngUkUe;J’ v.fh nghbauprpf; fQ;rp> Rf;F> 
nfhj;jky;ypf; fQ;rp> gQ;rKl;bf; fQ;rp nfhLf;fyhk;. 
3. fha;r;R Mwpa nte;ePu; mjpfk; gUfr; nra;jy;. 
4. Ruj;ijf; fl;Lg;gLj;jf;$ba kUe;Jfis toq;Fjy.; 
5. Ruj;jpw;F Mfhjg; nghUl;fis ePf;Fjy; v.fh. ghy;> vz;nza;> 
,sePu;> Fspu;e;j NrhW> ,iwr;rp> Nfhop> khq;fha;> gioa fQ;rp 
Kjypa czT tiffis ePf;fNtz;Lk;. 
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LINE OF TREATMENT 
 Siddha treatment is not only for complete healing but also prevention 
and rejuvenation. It is essential to know the Disease, Etiology, Mukkutra Nilai,and 
Nature of the patients and severity of the illness.The aim of the treatment is based 
on 
 To bring the three kuttrams into normal equilibrium state. 
 Treatment of the disease by internal medicines. 
 Diet regimen 
 Restoration 
 Regarding the treatment of suram, various medicines are stated in siddha 
literatures. Among them the trail medicine “Vettumaran kuligai” has been 
selected. 
 
Dosage: 
 65mg size, 1 pill,  twice a day(According to age). 
Adjuvant: 
 Ginger juice 
  
 During the course of the treatment, the patients were advice to follow 
certain restrictions regarding diet and physical activities. 
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REVIEW OF LITERATURE 
MODERN ASPECT 
FEVER 
“Fever” also known as “pyrexia” and febrile response. Pyrexia is from the 
Greek word.’ Pyr’ means ‘fire’. “Febrile” is from the Latin word. Febrile means 
fever and archiacially known as ague. Fever is one of the most common medical 
signs.it is part of about 30% of health care visit by children. 
HISTORY 
A number of types of fever were known as early as 460 BC to 370 BC when 
Hippocrates was practicing medicine including that due to malaria (tertian or every 
2 days and quartan). It also became clear around this time that fever was a 
symptom of disease rather than a disease in and itself. 
“Fever has evolved as a host defense mechanism which was preserved 
within the animal kingdom through hundreds of millions of years of evolution”. 
DEFINITION 
Fever is a controlled increase in body temperature over the normal values 
for an individual.  
The normal body temperature in children is higher as compared to adults, 
varies between 36.5° C and 37.3° C  {98.4°-100° F}  on rectal measurement and 
exhibits a normal circadian diurnal variation being lowest between midnight and 6 
am and maximum between 5 pm and 7 pm. 
Body temperature is regulated by thermo sensitive neurons located in the 
preoptic or anterior hypothalamus that respond to changes in blood temperature as 
well as to direct neural connection with cold and warm receptors located in skin 
and muscle . Thermoregulatory responses include redirecting blood to or from 
cutaneous vascular beds, increasing or decreasing sweating, extracellular fluid 
volume regulation (via arginine vasopressin) and behavioral response, such as 
seeking a warmer or cooler environmental temperature. 
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EPIDEMIOLOGY 
 About 5% of people who go to an emergency room have a fever. 
MEASUREMENT 
The core body temperature can be measured inside the oral cavity, axilla, 
rectum, ear canal and over the temporal artery. 
The rectal method is the most accurate method for measuring temperature 
and fever is defined as rectal temperature of more than 38°C or 100°F. However 
measurement of rectal temperature is not always possible. 
In children below the age of 4 to 5 years axillary temperature may be used. 
The axillary temperature is on average 0.5°C to1°C (OR) 1°F TO 2° F lower than 
rectal temperature and fever is defined as axillary temperature 37.2° C or 99°F. In 
infants below the age of 3 months if the axillary method shows fever it should be 
confirmed by rectal temperature. 
In children above the age of 4 to 5 years the oral method is suitable. The 
oral temperature is 0.5° to 1°F (OR) 0.25° C to 0.5° C lower than the rectal 
temperature and fever is defined as oral temperature more than 37°.5 C or 99°.5 F. 
To measure temperature both mercury and electronic thermometers are 
available. The electronic thermometers are convenient and take only 30 seconds to 
record temperature, but are subjected to calibration errors. 
The mercury thermometers take 2-4 minute to record temperature and they 
are inexpensive and especially suitable for home use. 
Infrared thermometer used for measuring ear or temporal artery temperature 
measure rapidly and closely approximate to rectal temperature,but are expensive. 
HOW TO MEASURE TEMPERATURE 
AXILLARY TEMPERATURE 
For taking an axillary temperature clean the thermometer from bulb to stem. 
Check the thermometer for minimum reading. Wipe away the axilla with a dry 
cloth and place the bulb of the thermometer in the axilla. Place the same arm 
against the chest wall to hold the thermometer in place. Keep in place for 3-5 
minutes for maximum reading. While taking temperature in axilla take care to 
direct the tip of the thermometer towards the apex of the axilla 
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.ORAL TEMPERATURE 
This method is used for the children above 5 years of age. It cannot be used 
for children with convulsions, mental retardation and with altered consciousness. It 
must be confirmed that the child has not had anything cold or hot by mouth within 
15 minutes before inserting the thermometer in the mouth. 
The child should be explained that the thermometer will be placed under the 
tongue and left there for five minutes. Then the thermometer should be cleaned 
from the bulb to stem and the bulb should be placed under the tongue. It should be 
removed from the mouth and should be cleaned from the stem to the bulb and 
reading should be taken. 
RECTAL TEMPERATURE 
This measure should be used with precaution while using for a new born 
baby, infants and unconscious patients. The child should be placed on the mother’s 
lap, if possible on a bed. Neonates may be placed on their back and their legs can 
be holding up exposing the anus.The thermometer should be wiped from the bulb 
to the stem and mercury should be brought to the minimum reading by shaking it. 
The Vaseline or jelly should be applied to the bulb anal area must be 
cleaned and buttocks should be separated. The bulb should be inserted through the 
anus up to 2-5 cm(for infants 2.5 cm and for elder children 5 cm ) in the rectum .It 
should be held in place for 3 minutes. Then it should be removed, wiped from stem 
to bulb and reading should be taken. 
ETIOPATHOGENESIS 
Causes of fever are varied including infections,vaccinations,biologic agents,tissue 
injury,malignancy,drugs,auto immune disease,granulamatous disease,metabolic 
disorder and inherited disorders such as mediterranean fever.These may result in 
the production of endogenous pyrogens,such as IL-(1),IL-(6).Tumor necrosis 
factor (TNF)-α,interferon β,Interferon γ and lipid mediators such as prostaglandin 
E-2,which alter the temperature set point in the anterior hypothalamus, leading to 
elevated body temperature. 
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 Types of fever: 
Continuous fever  
             Temperature remains above normal throughout the day and does not 
fluctuate more than 1°C in 24 hours.  e.g. lobar pneumonia, typhoid, meningitis, 
UTI, (or) typhus. 
            Typhoid fever may show a specific fever pattern, (wunderlich curve of 
typhoid fever), with a slow stepwise increase and a high plateau. 
Intermittent Fever: 
 The Temperature elevation is present only for a certain period, later cycling 
back to normal.  e.g. malaria, kala - azar, pyaemia, (or) septicemia. 
Following are its types: 
 Quotidian Fever, with a periodicity of 24 hours, typical of 
plasmodium falciparum (or) plasmodium knowlesi malaria 
 Tertian Fever: 
(48 - hour periodicity), typical of plasmodium vivax (or) 
plasmodium ovale malaria. 
 Quartan fever: 
72- hour periodicity, typical of plasmodium malaria. 
 Remittent Fever: 
   Temperature remains above normal throughout remains above 
normal throughout the day and fluctuates more than 1°C in 24 hours, e.g., infective 
endocarditis, brucellosis. 
Pel- Ebstein fever: 
 A specific kind of fever associated with Hodgkin’s Lymphoma, being high 
for one week and low for the next week and so on. 
Febrile neutropenia: 
 It is a fever in the absence of normal immune system function.  Because of 
the lack of infection fighting neutrophils, a bacterial infection can spread 
rapidly.This fever is, therefore, usually considered to require urgent medical 
attention. 
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Febricula: 
 It is an old term for a low grade fever, especially if the cause is unknown, 
no other symptoms are present, and the patient recovers fully in less than a week. 
Hyperpyrexia: 
 Hyperpyrexia is a fever with an extreme evaluation of the body temperature 
greater than (or) equal to 41.5°C (106°.7 F).  Such a high temperature is 
considered a medical emergency as it may indicate serious underlying condition 
(or) lead to significant side effects.  The most common cause is an intracranial 
hemorrhage.  The most common cause other possible causes include sepsis, 
Kawasaki syndrome, neuroleptic malignant syndrome, drug effects, serotonin 
syndrome and thyroid storm. 
  
Infections are the most common causes of fevers. However, as the 
temperature rises other causes become more common.  
Infections commonly associated with hyperpyrexia, include, Roseola, measles and 
enteroviral infections.  Immediate aggressive cooling to less than 38.9°C ( 102°. 
0F) has been found to improve survival. 
Hyperthermia: 
 Hyperthermia is an example of a high temperature that is not a fever.  It 
occurs  from a number of causes.  Including heatstroke, neuroleptic malignant 
syndrome, malignant hyperthermia and idiosyncratic drug reactions. 
 Signs and symptoms 
 A fever is usually accompanied by sickness behavior, which consist of  
 Lethargy, 
 Depression, 
 Anorexia,  
 Sleepiness  
 Hyperalgesia 
 the inability to concentrate. 
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Fever in children symptoms 
Signs and symptom of fever may be obvious or subtle.The younger the 
child the more subtle the symptoms, 
Infant may, 
  Irritable 
  Fussy 
  Lethargic 
  Quiet 
 Feel Warm (or)hot 
 Not feed normally 
 Cry 
 Breathe rapidly 
 Exhibit changes in sleeping (or) eating habits 
Verbal children may complains of, 
 Feeling hotter (or) colder than others in the room who feel 
comfortable 
 Body aches 
 Headache 
 Sleeping more or having difficulty sleeping 
 Poor appetite 
CLASSIFICATION OF FEVER SYNDROMES 
1. Fever without focus 
2. Fever of unknown origin 
 
FEVER WITHOUT FOCUS 
This term refers to fever of acute onset and short duration(less than one 
week) without any localizing symptoms or any clinical sign on physical 
examination.It is a cause for concern as young children often shows limited signs 
of infection making it difficult to distinguish between serious bacterial infection 
from self limiting viral infection. 
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CLINICAL DIFFERENCE BETWEEN VIRAL AND BACTERIAL 
INFECTION 
 
VIRAL INFECTION BACTERIAL INFECTION 
Abrupt onset Insidious onset 
Duration usually 3-5 days May last for more than 7 days 
Prodorme usually present No prodorme 
Presence of rash almost always suggest 
viral etiology 
Very few bacterial conditions produce 
rash. 
No localized findings May have systemic localization and 
organomegaly 
Seasonal incidence No seasonal variation 
Many members in the family may be 
affected simultaneously 
Isolated cases 
Investigation usually normal Elevated WBC,CRP Positive culture 
positive x-ray suggestive of pneumonia 
Majority self limiting Majority require anti biotic therapy 
 
FEVER OF UNKOWN ORIGIN 
FUO is defined as fever greater than 101° C lasting for 3 weeks or more for 
which no cause is apparent after one week of outpatient investigation. Practical 
definition is fever greater than 101° F measured on several occasions over a 7 day 
period. 
 
CAUSES 
INFECTION 
Infections account for 60-70% cases in children 
 Enteric fever 
 Malaria 
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 UTI 
 TB 
 Chronic hepatitis 
 HIV 
 Mastoiditis 
 Sinusitis 
 Osteomlyelitis 
 Meningitis  
 Infectious mono nucleosis 
 Infective endocarditis 
 Brucellosis 
 Cytomegalo virus 
 Toxoplasmosis 
 Kala-azar 
AUTO –IMMUNE 
 Juvenile Rheumatoid Arthritis 
 Systemic lupus erythematous 
 Kawasaki disease 
 Inflammatory bowel disease 
 Poly-arteritis nodosa 
MALIGNANT 
 Leukemia 
 Lymphoma 
 Langerhan cell cystocytosis 
 
EVALUATION OF A FEBRILE PATIENT 
Evaluation of the causes of fever is important.If temperature is very high 
illness should be suspected. It is useful to classify fever as short duration fevers 
and prolonged fevers as etiology and management differs. The pattern of fever is 
sometimes useful in arriving at a diagnosis. 
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Intermittent fevers are characteristic of malaria. Biphasic fevers are seen in 
illnesses such as dengue and leptospirosis and periodic fevers (fever syndrome 
with regular periodicity) are seen in cyclic neutropenia,PFAPA Syndrome 
(Periodic fever,Adenopathy,Pharyngitis,Apthous ulcers) and hyper 
immunoglobulin(IG)D-syndrome. 
SHORT DURATION FEVER 
Access to localizing symptoms the type of  fever can be evaluated. 
A) Fever with an identifiable focus 
 Furuncles 
 Abscess 
 Lymphadenopathy 
 Tonsillitis 
 Joint-bone infections 
 Rash 
 Hepato -splenomegaly 
B) FEVER WITH RESPIRATORY SYMPTOM 
(1)Upper respiratory 
 Ear discharge 
 Head ache 
 Acute otitis media 
 Sinusitis 
(2) Lower respiratory 
 Tachypnea 
 Distress 
 Pneumonia 
 Empyema 
C) FEVER WITH ABDOMINAL SYMPTOMS 
 Diarrhea 
 Abdominal pain 
 Dysuria 
D) DERMAL INFECTIONS 
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MANAGEMENT OF FEVER 
 Tepid water sponging 
 Anti-pyretics 
 Fluid management 
 Appropriate anti-biotics 
 Diet 
TEPID WATER SPONGING 
A tepid sponge helps to reduce the body temperature, to relieve discomfort, 
to soothe the nerves and promote sleep. 
 
Tepid water sponging procedure 
The purpose of the tepid sponge explains the mother and the patient, if 
possible. The required articles should be at the bedside and the patient should be 
screened.  The patient should be covered with the light sheet and his/her clothes 
should be covered.  The bed should be protected with the mackintosh and towel. 
Tap water should be taken is a bath basin and the sponge cloth should be 
put in the water.  The wash cloth should be sponged from the shoulder to tip of 
fingers in long strokes, using alternate sponge cloth.  The water should be changed 
during the procedure (or) ice can be added to the water to maintain the temperature 
of the water. Usually the sponge is continued for 15 minutes.  After completing the 
sponge, the clean clothes should be put on and the patient should be made 
comfortable. 
After completing the procedure, the soiled linen should be changed and dry 
bed should be provided. 
The patient’s temperature, pulse and respiration should be assessed and 
recorded. 
The patient should be observed throughout the procedure. If  he/she 
develops a chill, the procedure should be stopped patient should be dried & 
covered. 
 
 
40 
 
Preventive measures 
 To avoid infectious and vector borne fevers we should take preventive 
measures. 
 Vaccinations 
 Improving self hygine 
 Improving sanitation 
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Fig.1. Etiopathogenesis of fever 
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Fig.2 Clinical assessment in short duration fever 
 
  
43 
 
 
 Fig.3 Clinical assessment in long duration fever 
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MATERIALS AND METHODS 
The study on clinical evaluation of the disease “suram” with the trial drug 
“vettumaran kuligai” was carried out in postgraduate kuzhanthai maruthuvam 
department at Government siddha medical college, palayamkottai.20 patients of 
both male and female children were selected for the studies and admitted in 
postgraduate kuzhanthai maruthuvam In patients ward for minimum three days 
and advised for further follow up as out- patients. Another 20 patients are treated 
with trial drug in the out patients ward. 
SELECTION OF PATIENTS 
The present study covers both male and female children of pediatric age 
groups. All cases were carefully examined before admission.  Those who fulfilled 
the criteria of “suram” according to the clinical features in siddha and modern 
reviews were selected with the aid of questionnaire.  
STUDY PARTICIPANTS 
INCLUSION CRITERIA 
1. AGE : 1 to 12 yrs 
2. SEX : Both male and female children 
3. Infectious fever due to, 
Respiratory infection 
Viral infections 
Urinary tract infections 
Bacterial infections 
4. Patient parents who are willing for admission and stay in IPD or   willing to  
          attend without drop 
5. Parents of the child who cooperate for investigations 
6. Parents willing to sign the informed consent stating that he/she  will  
consciously stick on to the treatment during seven days but  can  OPD out 
of trial of his or her own conscious discretion.  
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 EXCLUSION CRITERIA 
  1. Children above 12 years 
  2. Fever due to brain infection 
  3. Fever due to malignancy 
  4. Fever of unknown origin 
  5. Patient with other serious illness who are on medical 
   Emergencies 
Withdrawal criteria 
 1. Fever more than 7 days not responding to the trial drug 
2. If any adverse effect reactions and altered symptoms 
occurred during the drug trial 
3. Intolerance to the drug 
4. Patient turned unwilling to continue in the course of 
trial 
5. Occurrence of any serious illness 
Test and assessments 
1.Clinical assessment 
A .Symptoms of respiratory infections- fever, 
cough throat pain, sneeze, running nose, 
wheeze… 
B Genito urinary symptoms- fever, 
dysuria,frequency of micturition, loin pain… 
2.SIDDHA ASSESMENTS 
 Nilam,   
 kaalam, 
 Uyirthaathukkal  
 Udarthaathukkal,   
 Envagai    thervugal 
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3. Investigations 
 a)Blood investigation 
Total WBC count, 
Diffrential count of WBC, 
Erythrocyte sedimentation rate, 
 Hemoglobin , 
ASO-titer 
RA factor, 
Total RBC count 
CRP, 
blood glucose 
 b) Urine 
Albumin, 
Sugar, 
Deposits, 
 RBC,  
Pus cells 
Bile salt,  
Bile pigments 
 c) Stool 
   Ova, 
 Cyst,  
Stool culture 
 D) Special tests 
Peripheral blood smear, 
Blood culture, 
Mantoux test, 
X-ray 
 e) Siddha investigation 
   Neerkuri, 
  Neikuri. 
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Details of trial drug 
Medicine  : Vettu maran kuligai 
Reference  : pharmacopeia of hospital of Indian 
Medicine,  Siddha. (Second edition) 
Dosage  : 65 milligram pills,1 along with  
ginger  Juice (according to age), two times per 
day 
Duration  : 3 days, if not completely  relieved, the 
     Drug may be continued for 7 days. 
Method of drug  
Administration : orally 
FORMS 
 FormI : Selection proforma-used before admission to the trial 
 Form II: Assessment proforma 
Conduct of the study 
Patients satisfying the inclusion and exclusion criteria will be 
admitted to the trial. Informed consent will be obtained from the patients. 
The trial drug vettumaran kuligai is given for 3 days for OP patients should 
visit the hospital once in two days. 
In each clinical visit clinical assessment is done and prognosis is noted .For 
IP patients the drug is given for three days and the clinical assessment is 
done daily. 
Laboratory investigations are done 0 day, 3rd day, 7th day of the 
trial. For IP patients who are not in situation to stay in the hospital for a 
long time are advised to attend the OPD for the further follow up. 
Pharmacoloigical analysis of the trial drug was done at the 
department of pharmacology, K.M. College of pharmacy, Madurai.the 
details are given in annexure. 
Biochemical analysis was done at the Department of Biochemistry, 
Government siddha medical college, Palayamkottai. 
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Anti- microbial study was done at Malar micro diagnostic Centre, 
Palayamkottai. 
The Acute toxicity study of the trail drug was done at the department of 
Pharmacology, KMCH College of pharmacy, Coimbatore. 
The details and the results are given in the annexure. 
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DRUG REVIEW 
Preparation of dissertation drug  “Vettumaran Kuligai.” 
 
Usage  : Internal medicine 
Reference : Pharmacopoeia of hospital of indian medicine,part-II-siddha. 
INGREDIENTS: 
 NAME    QUANTITY 
 Venmilagu  -  0.125gm  
 Thippili  -  0.125gm 
 Omam  -  0.125gm  
 Naabi   -  0.125gm 
 Porikaaram  -  0.125gm 
 Lingam  -  0.100gm 
 Inji   -  2gm 
 Purified water -  Required amount 
 The drug ratio according to literature, it has been maintained during the 
preparation of the trial drug. 
Purification of drugs 
 In our siddha traditional system purification methods of drugs are used to 
decrease the toxicity and increase the bioactivity of the active ingredients. 
Purification of Naabi: 
 Root tubers are cut into small pieces and kept in a clay pot; the cow’s urine 
is added into the pot and kept in the sunny days for three days. Replacing the 
cow’s urine every day. The tuber bark is peeled out and washed and dried to make 
naabi as pure and harmless. 
Purification of porikaram 
 Fried under heat until the water content of vengaram is 
evaporate.  
Purification of lingam 
 Soaking  in lemon juice for three days. Replace lemon juice every day. 
Then washed in water and dried in sunlight 
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Purification of inji  
 Peeled the inji(ginger) and cleaned with water. 
Purification of other three drugs: 
 The drugs venmilagu, thippili, and omam are fried under mild 
heat. 
Method of preparation 
 Except inji all the other purified drugs are powdered and sift. Inji juice is 
prepared. Then all the powderd drugs are mixed well and kept into the kalvam the 
manual grinding instrument,and grind for three hours,by adding inji(ginger)juice. 
After grinding, prepared pills of milagu size (65 mg) and dried up in shade. 
Indication  : All kinds of fever,janni,ceetham, etc., 
Dosage  : 65 milligram size pills, 1-2 pills (according  to age)  
Adjuvant  : Ginger juice 
Expiry  : One year 
  ‘tpuypLK au;ejkhj; jpiufLF gf;Ftk; 
   kpspUNj Dhwy;jPdPu; 
   nfhs;shW Nkhuhz;L.......”  
      -Fzghlk; - jhJ [Pt tFg;G  
Drug storage 
 The trial drug “vettumaran kuligai” stored in clean and dry glass bottles. 
Dispensing 
 The trial drug  “vettumaran kuligai” given in pills form in packets. 
Properties of the dissertation drugs  
1.ntz;kpsF 
NtW ngau;fs; : fypid> fwp> fhak;> jpuq;fy;> 
kiyahsp 
Botanical name : Piper nigrum 
 Family  : Piperaceae  
 English name : White pepper 
 kpsF gok; gOj;J Njhy; cjpu;e;jhy; mJ nts;iskpsF 
vdg;gLfpwJ. 
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 gad;gLk; cWg;G : gok; 
 Rit   : ifg;G> fhu;g;G 
 jd;ik  : ntg;gk; 
 gpupT   : fhu;g;G 
nghJFzk;:- 
kpsF:- 
 jPahfp naq;Fk; jphpAkij ahtj;J 
 Nkhahk nyg;gbA Kz;lhf;fhw; - ghahJ 
 Nghe;jpkph;th jq;fpue;jp Gz;zPUk; kz;zth;f;Fk; 
 fhe;jpnka;th  jr;rYg;igf; fha; 
         -Njud; ntz;gh. 
 kpsF tsp> jP> fgf;Fw;wq;fs; ,it midj;ijAk; ePf;Fk;. md;wpAk; 
jpkph;thjk; foiy> tsp> rsp ,itfisAk; mfw;Wk;. 
nts;is kpsF:- 
 nts;is kpsfUe;j tPW fpufzpg; Nghk; 
 js;S fgthje; jhNdFk; - cs;s 
 Ruk; NghFe; jPgdkhk; njhy;Nkfk; Nghkpj; 
 jpuk;ghh; vth;fSf;FQ; nrg;G 
       - mfj;jpah; Fzthflk; 
 nts;is kpsfpdhy;  ehl;gl;lf; fopr;ry;> Iatsp Ruk;> Ruk;> Nkfk;  
,it NghFk;. grp cz;lhFk;. 
Chemical constituents 
 piperine,  
 piperamide,  
 pipericide 
 6-sarmentine 
Pharmacological actions:  
 Stimulant , 
 Antiperiodic, 
 Anti vaatha, 
 Anti-inflammatory , 
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 Anti-diarrheal 
 Analgesic 
Piper nigrum also having “bioavailability enhancing property” 
 
2.jpg;gpyp 
NtWngau;fs; : fhkd;> FNlhup> Nfhyfk;> 
NfhioaWf;fp> ruk;> rhb 
 Botanical name : Piper longum 
 Family  : Piperaceae 
 English name : Long pepper 
 Rit   : fhu;g;G 
 jd;ik  : ntg;gk; 
 gpupT   : ,dpg;G 
nghJFzk; 
  ‘fl;b najpu;epd;W fLNehnay; yhk;gzpAk; 
   jpl;b tpidafYk; Njfnkj;j -Gl;bahk; 
   khkDf;F khkndd kw;wtu;f;F kw;wtdha; 
   fhkndd;De; jpg;gpypf;Fk; if’ 
- Njud;ntz;gh 
  jpg;gpyp fLikahd Iag;gpzpfisAk; 
  mfw;wp> clw;F td;ikaspf;Fk; 
Chemical constituents :   
 Piperolactone, 
 Piperine, 
 Sylvatin 
 Methyl piperate , 
 Piperlongimine 
Pharmacological actions: 
 Stimulant,  
 Carminative 
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3.Xkk; 
 NtWngau;fs; : mrNkhjk;> jpg;gpak; 
 Botanical name : Trachyspermum ammi, 
 Family  : Apiaceae 
 English name : Bishop’s weed 
 gad;gLk; cWg;G : tpij 
 Rit   : fhu;g;G 
 jd;ik  : ntg;gk; 
 gpupT   : fhu;g;G 
nghJFzk;: 
 ‘rPjRuq; fhrQ; nrhpahkhe; jk;nghUky; 
 Ngjpapiur; ry;fLg;G Nguhkk; - XjpUky; 
 gy;nyhLgy; %yk; gfkpitNeh nad; nrANkh? 
 nrhy;nyhLNghk; Xknkdr; nrhy; “ 
        - Fzghlk; - %ypif 
,jdhy; IaRuk;> ,Uky;> nrhpahke;jk;> nghUky;> fopr;ry;> Cop> 
Flypiur;ry;> ,iug;G> gy;Neha;> gfk; ( Fa;aNuhfk;) ,itfs; Nghk;. 
Chemical constituents :  
 Limonine,  
 carvone,  
 carvacol  
 γ-terpentine, 
 α-terpentine 
Seeds also contains nutritional substances like  
 Calcium,  
 Iron , 
 Nicotinicacid, 
 Thymine and  
 phosphorous.  
Pharmacological actions:  
 Anti-fungal,  
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 Anti-bacterial 
 Anti-inflammatory, 
 Anti-oxidant 
 Antifilarial 
 Thymol and carvacol are known to be either bactericidal or bacteriostatic 
agents depending on the concentrations. 
 Thymol kills the bacteria resistant to even prevalent third generation anti-
biotics and multidrug resistant microbial pathogens. 
4.ehgp 
 NtWngau;fs; : ehgp> trehgp> tplk;> kUjk;  
 gad;gLk; cWg;G : Ntu;f;fpoq;F  
 Botanical name : Aconitum ferox 
 Family  : Rannunculaceae 
 English name : Monk’s hood, Wolf’s bane 
 Rit   : ifg;G 
 jd;ik  : ntg;gk; 
 gpupT   : fhu;g;G 
ehgp tiffs; 
 1. ntz;ehgp 
 2. nre;ehgp 
 3. ePh;ehgp 
 4. fU ehgp 
nghJFzk;:- 
  thjtyp ke;jkwy; khwhf; fgg;gpzpfs; 
  XJFl;L Fd;ke;Njd; XLq;fhz; - fhjyh;jk; 
  Gj;jpNah lhUapUk; G+Tk; tidFoNy 
  Rj;jp nra;j ehtpapd; Ngh; nrhy;. 
       - Fzghlk; -%ypif 
ehgpapdhy; fPo;tha;f;fLg;G> nrhpahik> Iag;gpzpfs;> ngUNeha;> Fd;kk;> 
Njs; eQ;R ePq;Fk;. 
midj;J tif ehgpapdhYk; Ruk; NghFk;. 
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trehgp -nghJFzk ; 
  fbanjhU Fl;lq; fdj;j tp~rd;dp 
  nfhbanjhU Fd;kk; FiyAk;- gbapy; 
  jsuj;jp ntg;GlNd jhfRuk; jPUk; 
  tsh;gr;ir ehtpjid tho;j;J 
        Fzghlk;- %ypif 
 gr;ir ehgp FiwNeha;> eQ;R> Kg;gpzp> Fd;kk;> vYk;gpd;  #L> Ruk;> 
ePh;Ntl;if ,itfis tpyf;Fk;. 
Chemical constituents:  
 Bikhaconitine,  
 Pseudaconitine 
 Chasmaaconitine,  
 Indoaconitine 
 Veratoyl pseudoaconitine 
Pharmacological actions:  
 Anti periodic,  
 Antipyretic 
 Analgesic,  
 Anti-inflammatory 
 Aconitum is the valuable drug as well as the toxic material.It can be used 
safely after purification processing. The TLC studies have shown that 
pseudaconitine and aconitine were converted into veratoyl pseudoaconine and 
benzoylaconine respectively in traditional ayurvedic sodhana method which is 
similar process in siddha system. 
5.,Q;rp 
 NtWngau;fs; : my;yk;> Mu;j;jufk;  
 gad;gLk; cWg;G : Ntu;f;fpoq;F 
 Rit   : fhu;g;G 
 jd;ik  : ntg;gk; 
 gpupT   : fhu;g;G 
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,Q;rp  nghJFzk ; 
  “ ,Q;rpf; fpoq;Ff; fpUky; Iak; Xf;fhsk; 
    tQ;rpf;FQ; rd;dpRuk; td;Ngjp - tpQ;Rfpd;w 
    #iyaWk; thjk;Nghe; Jhz;lhj jPgdkhk; 
     NtiyAWq; fz;zha; - tpsk;G 
       - mfj;jpah; Fzthflk; 
   
    ,Q;rpapd; FzNk njd;wp ay;Gl Diuf;ff; NfsPh; 
    mQ;rpLQ; rd;dpnay;yh kfd;wpLk; gpj;j Njhlk; 
    neQ;rpdp ypUkw; Nfhio nefpo;e;jpLk; fgq;fs; jd;id 
     kpQ;rpdp tUNkh ntd;W tpsk;gpLk; NjtEhNy 
        - VL 
 ,Q;rp XU fw;g kUe;J. ,J fgf; Fw;wj;ijg; Nghf;Fk;. 
 ,Q;rpapy; ,Uky;> <is> nts;Nshf;fhsk;> moy; Fw;wk;> 
tsp#iy> Kf;Fw;w Neha;fs;> Nfhiof; $l;lk;> nrhpahf; 
fopr;ry; ,it NghFk;. 
  grpAz;lhFk;. 
Chemical constituents :  
 Gingerols,  
 β sitosterol  
 Palmitate, 
 Isovannilin 
 Methyldiacetoxy-(4)-gingerol 
Nutritional components:  
 Iron, 
 Calcium, 
 Phosphorous, 
 Potassium 
 Thiamine, 
 Riboflavin, 
 Niacin, 
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 VitaminC 
Pharmacological actions:  
 Carminative, 
 Digestive. 
 
In recent studies, ginger is reported for various medicinal properties. They are, 
 Hepatoprotective 
 Nephroprotective 
 Larvicidal activity 
 Anti-bacterial 
 Analgesic 
 Anti-inflammatory 
6.,ypq;fk; 
 NtWngau;fs; : Mz;Fwp> ,q;Fypfk;> 
     filtd;dp> fu;g;gk;> fypf;fk;> 
     fhQ;rdk; 
 English name : Cinnabar, Vermilion   
 Chemical name : Redsulphide of Mercury 
nghJFzk; 
 ‘NgjpRuQ; re;ep ngUtpuz ePnuhLj 
 fhjfb fhrq; fug;ghd;Gz;-Nzhj 
 TUTypq;f rq;fjkh A+Wfl;b Ak;Nghq; 
 FUtpypq;f rq;fkj;ijf; nfhs;’ 
 ‘epyj;jpy; vOe;jgpzp ePq;fhf; fpue;jp 
  ryj;JlNd #iyntb jhdfw;Wk;-gyj;jjhk; 
  rhjpypq;fj;jpd; Fzj;ijr; rhw;wpNdd;rd;dp 
  Kjy; XJRuk; NghNk xope;J 
- Fzghlk;-jhJ[Pt tFg;G 
 Njhw;wj;jpy; ghjur cUf;fhfpa rpte;j epwKila ypq;fk;> mJ 
Nru;e;j kw;w kUe;JfSk; ,ur Fzj;ijf; nfhz;L Jd;gj;ij cz;L 
gz;Zfpd;w Ngjp> Ruk;> rd;dp> jPuhg;Gz;> mjp%yk;> fug;ghd;> rpuq;F> 
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Fl;lk;> fpue;jp> nfhLik nra;Ak; R+iy> clypy; kiwe;jpUf;Fk; 
gpzpfisAk; ePf;Fk;. 
 Rit   : ,y;iy 
 tPupak;  : ntg;g tPupak; 
Pharmacological actions:  
 Restorative, 
 Tonic, 
 Alterative 
Cinnabar is less toxic than many other form of Mercury. It contains insoluble 
Hg2+and Hg+. 
 
 
7.ntq;fhuk; 
 English name : Borax  
 Chemical name : Sodium borate 
 Chemical formula : Na2B 4O 7. 10H 2O  
 NtWngau;fs; : nghupfhuk;> fhuk;> lq;fdk;> 
     Jhkj;ijalf;fp 
 Rit   : ,dpg;Gld; $ba Jtu;g;G 
 tPupak;  : ntg;gk; 
 nra;if  : Fspu;r;rpAz;lhf;fp 
     rpWePu;ngUf;fp 
     cly;Njw;wp 
ntq;fhuk; - nghJFzk ; 
 
‘nrhwp  Gilnaz; Fd;keik Nrhhpahrk; 
 gwpfpufzp fy;Yhdk; gd;Ndha; - newpiaj; 
 jlq;fzq;f gq;fpUkp rh;g;gtplQ; re;ep 
 aplq;fzq;f yf;fpw;Ngh nkz;” 
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‘ ntq;fhuQ; Nrj;Jkj;ij NtWgz;Z NkfLF 
  jq;Frpy ePh;Kwpaj; jhd; thq;Fk;” 
       Fzghlk; - jhJ [Pt tFg;G 
ntq;fhuj;jpdhy; fg Mjpf;fk;> GO> ghk;G Kjypaitfshy; cz;lhFk; 
eQ;R> re;jpghjk; Kjypa Neha;fs; ePq;Fk;. 
      
 ntq;fhuk; fgj;ijAk;> ePu;g;gpzpiaAk; ePf;Fk;. 
 Fspu;Ruk; tuhky; jLf;f ntq;fhuj;ij 260 kp.fp. Kjy; 520 kp.fp. 
tiu ntw;wpiyAld; nfhLj;jy; Ntz;Lk;. 
Borax possesses  
 Antiseptic,  
 Antifungal,     
 Antiviral  
 Anti- inflammatory actions. 
 It is essential in maintaining calcium, magnesium and phosphorus in our 
body. 
 Borax has the capacity to nullify the effects of poisoning of all varieties. 
 Borax is known as an antidote for aconite poison.so that majority of the 
aconite containing formulation contain borax. 
                                          -Indian journal of history of science47, 2(2012). 
    
 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
61 
 
 
 
 
 
62 
 
 
 
 
 
63 
 
 
RESULTS AND OBSERVATIONS 
 
Results were observed with respect to the following criteria.  
1. Sex 
2. Age 
3. Religion 
4. Economic status of the patient 
5. Diet 
6. Paruva kaalam 
7. Thinai 
8. Clinical features of SURAM during admission 
9. Three dosha theory 
10. Ezhu udarkattugal 
11. Envagai thervugal 
12. Neerkuri, Neikuri 
13. Results after treatment 
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AGE DISTRIBUTION 
 
Sl.No. Age 
No.of 
cases 
Percentage 
1.  1 – 6 months (Kaapu paruvam) 0 0% 
2.  6 – 12 months (Senkeerai paruvam) 0 0% 
3.  
1 – 3 years(Thalattu, sappani, Mutha and 
Varugai paruvams) 
10 25% 
4.  
3 – 6 years (Ampuli sitril, siruparai, siruthaer 
viduthal – male child. Ammanai, 
Neeraduthal, Oojal – female child) 
17 42.5% 
5.  
6 – 12 years (Siruparuvam – male child. 
Paethai and perthumbai – female child) 
13 32.5% 
 
 
 
Among the 40 cases 25% belonged to 1-3 years, 42.5% belonged to 3-6 
years, 32.5% belonged to 6-12 years.  
0%
10%
20%
30%
40%
50%
1 – 6 
months
6 – 12 
months 1 – 3 years 3 – 6 years 
6 – 12 years 
0% 0%
25%
42.50%
32.50%
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SEX DISTRIBUTION 
 
Sl. no. Sex No.of Cases Percentage 
1. Male children 25 62.5% 
2. Female children 15 37.5% 
 
 
 Among the 40 patients selected 37.5% patients were Female children and 
62.5% patients were Male children. 
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RELIGION DISTRIBUTION 
 
Sl. no. Religion No.of Cases Percentage 
1.  Hindu 34 85% 
2.  Christian 4 10% 
3.  Muslim 2 5% 
 
 
 Out of the 40 cases, 85% were Hindus 10% were Christians and 5% were 
Muslims 
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SOCIO– ECONOMIC STATUS OF THE PATIENT 
 
Sl. no. 
Socio – 
Economic Status 
No.of Cases Percentage 
1.  Poor  26 65% 
2.  Middle 10 25% 
3.  Rich 4 10% 
 
 
 Out of the 40 patients, 65% of cases were poor and 25% were middle class 
people and 10% of cases were rich. 
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DIETARY HABITS 
 
Sl. no. Diet No.of Cases Percentage 
1.  Vegetarian 4 10% 
2.  Mixed 36 90% 
 
 
 90% of cases have mixed diet and 10% of cases were vegetarian diet.  
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SEASONAL HABITS 
 
Sl. 
no. 
Paruva kaalam 
No.of 
Cases 
Percentage 
1.  Kaar kaalam (Aavani & puratasi) - 0% 
2.  Koothir kaalam (Iyppasi & Karthigai) - 0% 
3.  Munpani kaalam (Markazhi & Thai) 15 37.5% 
4.  Pinpani kaalam (Masi & Panguni) 12 30% 
5.  Elavenil kaalam (Chithirai & Vaigasi) 13 32.5% 
6.  Muthuvenil kaalam (Aani & Aadi) - 0% 
 
 
 Among the 40 cases selected, 37.5 % cases were affected in Munpani 
kaalam, 30% cases were affected in Pinpani kaalam, 32.5% cases were affected in 
Elavenil kaalam. 
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THINAI REFERENCE 
 
Sl. 
no. 
Thinai No.of Cases Percentage 
1.  Kurinji (Hill area) - - 
2.  Mullai (Forest area) - - 
3.  Marutham (Fertile area) 40 100% 
4.  Neithal (Coastal area) - - 
5.  Paalai (Desert area) - - 
 
 
 40 cases (100%) belongs to Marutha nilam. 
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CLINICAL PRESENTATION 
RESULTS: 
(i) Prognosis assessment of signs and symptoms: 
Sl. 
No. Signs and Symptoms 
Present during 
admission (No. of 
case) 
Improvement of 
signs & 
symptoms% 
1.  Increased Temperature 40 90% 
2.  Chills 3 100% 
3.  Rashes 2 100% 
4.  Sneezing 2 100% 
5.  Running nose 12 100% 
6.  Nasal block 1 100% 
7.  Myalgia 5 100% 
8.  Headache 7 100% 
9.  Throat pain 3 100% 
10.  Cough 4 100% 
11.  Expectoration 13 100% 
12.  Chest pain   
13.  Breathlessness   
14.  Nausea 1 100% 
15.  Vomitting 2 100% 
16.  Hemetemesis   
17.  Jaundice   
18.  Abdomen pain 2 100% 
19.  Diarrhoea   
20.  Dysuria 2 100% 
21.  Hematuria   
22.  Oliguria   
23.  Retro orbital pain   
24.  Photophobia   
25.  Neck pain   
26.  Joint pain 1 100% 
27.  Ear ache 2 100% 
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85
90
95
100
100
Percentage
1
1. Increased 
Temperature 90
2. Chills 100
3. Rashes 100
4. Sneezing 100
5. Running nose 100
6. Nasal block 100
7. Myalgia 100
8. Headache 100
9. Throat pain 100
10. Cough 100
11. Expectoration 100
12. Chest pain
13. Breathlessness
14. Nausea 100
15. Vomitting 100
16. Hemetemesis
17. Jaundice
18. Abdomen pain 100
19. Diarrhoea
20. Dysuria 100
21. Hematuria
22. Oliguria
23. Retro orbital pain
24. Photophobia
25. Neck pain
26. Joint pain 100
27. Ear ache 100
Results
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UYIR THATHUKKAL 
i. Derangements of Vadham: 
Sl. 
no. 
Types of Vadham 
No.of Cases 
(out of 40) 
Percentage 
1.  Praanan (gpuhzd;) 20 50% 
2.  Abaanan (mghdd;) 3 7.5% 
3.  Samaanan (rkhdd;) 30 75% 
4.  Uthaanan (cjhdd;) 13 32.5% 
5.  Viyaanan (tpahdd;) 40 100% 
6.  Naagan (ehfd;)  0% 
7.  Koorman ($Hkd;) 4 10% 
8.  Kirukaran (fpUfud;) 13 32.5% 
9.  Devathatthan (Njtjj;jd;) 10 25% 
10.  Dhananjeyan (jdQ;nrad;)   
 
 Due to the derangement of vadham the following symptoms occur. Praanan 
deranged in 50% of patients, it causes breathing difficulties and poor appetite. 
Abaanan deranged in 7.5% of patients. Samaanan deranged in 75% of patients, it 
cause poor appetite. Uthaanan deranged in 32.5% of patients, it causes gradual 
emaciation. Viyaanan deranged in 100% of patients, it causes decreased activity 
and increased temperature. 10% of patient causes by Koorman, Kirukaran 
deranged in 32.5% of patients, it causes cough, running nose and poor appetite. 
Devathatthan deranged in 25% of patients, it causes tiredness.  
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DERANGEMENTS OF PITHAM: 
 
Sl. 
no. 
Types of Pitham 
No.of Cases 
(out of 40) 
Percentage 
1.  Anal Pitham (mdy; gpj;jk;) 30 75% 
2.  Ranjagam (,uQ;rfk;) 20 50% 
3.  Saadhagam (rhjfk;) 10 25% 
4.  Praasagam(gpuhrfk;) 0 0% 
5.  Aalosagam(MNyhrfk;) 0 0% 
 
 Due to the derangement of pitham the following symptoms occur. Anal 
pitham deranged in 75% of patients, it cause poor appetite. Ranjagam deranged in 
50% of patients.Saadhagam deranged in 25% of patients 
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ii. Derangement of Kabam: 
Sl. 
no. 
Types of Kabam 
No.of Cases 
(out of 40) 
Percentage 
1.  Avalambagam (mtyk;gfk;) 20 50% 
2.  Kilethagam (fpNyjfk;) 30 75% 
3.  Pothagam (Nghjfk;) - 0% 
4.  Tharpagam (jw;gfk;) 4 10% 
5.  Santhegam (re;jpfk;) 1 2.5% 
 
 Due to the derangement of kabam the following symptoms occur. 
Avalambagam deranged in 50% of patients, it causes cough. Kilethagam deranged 
in 75% of patients, it causes poor appetite. Tharpagam deranged in 10% of 
patients, it causes redness of eyes. Santhegam deranged in 2.5% of patients, it 
causes joint pain. 
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UDAR THATHUKKAL 
 
Sl. 
no. 
Udar Thathukkal 
No.of Cases 
(out of 40) 
Percentage 
1.  Saaram  (rhuk;) 30 75% 
2.  Senneer (nre;ePH) 20 50% 
3.  Oonn(Cd;) 10 25% 
4.  Kozhuppu(nfhOg;G) 8 20% 
5.  Enbu(vd;G) 0 0% 
6.  Moolai(%is) 0 0% 
7.  
Sukkilam / Suronitham(Rf;fpyk; 
/ RNuhzpjk;) 
0 0% 
 
 In ezhu udar kattugal saaram affected in 75% of patients. Senneer affected 
in 50% of patients. Oonn affected in 25% of patients due to Kozhuppu affected in 
20% of patients. 
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ENN VAGAI THERVUGAL 
 
Sl. 
no. Enn vagai thervugal 
No.of Cases 
(out of 40) 
Percentage 
1.  Naadi  (ehb) 40 100% 
2.  Sparisam  (];ghprk;) 40 100% 
3.  Naa (eh) 8 20% 
4.  Niram (epwk;) 4 10% 
5.  Mozhi (nkhop) 2 5% 
6.  Vizhi (tpop) 6 15% 
7.  Malam (kyk;) 2 5% 
8.  Moothiram (%j;jpuk;) 4 20% 
 
In ennvagai thervugal, Naadi affected in all patients 100% due to the 
derangement of thrithodam. Fever and sweating was observed by sparisam, it 
deranged, in 100% of patients. Coated tongue and dryness of the tongue observed 
by naa, it affected in 20% of patients. Red colour, pale colour conjunctiva, nail 
buds are observed by niram, it altered in 10% of patients. Hoarseness of voice 
observed by mozhi, it affected in 5% of patients. Pallor of lower eyelids observed 
by vizhi, it affected in 15% of patients. Diarrhoea observed by malam, it altered in 
5% of patients. Decreased amount of urine observed by moothiram, it altered in 
20% of patients.  
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NEI KURI 
 
Sl. No. Neikuri Reference 
Characters of 
Urine 
No. of cases 
(out of 20) 
Percentage 
1. Vadha Neer Speads like Snake 6 35% 
2. Pitha Neer  Spreads like Ring 4 10% 
3. Kaba Neer Spreads like Pearl 10 55% 
 
 In urine examination of all 20 patients spreads like pearl in 10 patients 
(55%) spreads like snake in 6 patients (35%) spreads like ring in 4 patients (10%). 
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iii.  RADIOLOGICAL REPORT 
Sl. No. Nature of Lesion No. of cases Percentage 
1.  
Normal study 
X – ray chest pa view 
20 100% 
2.  
Ultra Sonogram Abdomen and 
pelvis (Normal) 
2 10% 
 
ii. Remarks: 
a. Among 20 I.P. Cases the results were observed as follows. 
 
 90% cases showed significant improvement. Because their signs and 
symptoms were reduced markedly. They were come under good response group. 
About 10% cases showed moderate improvement. 
 
 
 
Good, 90
Moderate  10
Sl. No. Remarks 
No. of cases (out of 
20) 
Percentage 
1.  Good 18 90% 
2. Moderate 2 10% 
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b. Among 20 OP cases the results were observed as follows: 
 
 90% cases showed significant improvement. Because their signs and 
symptoms were reduced markedly. They were come under good response group. 
About 10% cases showed moderate improvement. 
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   Out Patient Record 
Sl. 
No. 
OP 
No. 
Name 
Age / 
Sex 
No of days 
treated 
Remarks 
1.  145 Harshavarthan  3MC 6 Days Good 
2.  971 Isakkiraja 12MC 3 Days Good 
3.  8875 Arvinthan 7FC 6 Days Fair 
4.  2893 Kumar 11MC 4 Days Good 
5.  3671 Pavithra 6MC 3 Days Good 
6.  4764 Sujitha 3FC 7 Days Good 
7.  5161 Ajay 3 ½ MC 5 Days Good 
8.  8364 Varshini 1 ½ FC 4 Days Fair 
9.  8408 Barath kumar 7MC 3 Days Good 
10.  9540 Stalin 5MC 7 Days Good 
11.  10256 Heachandran 8MC 5 Days Good 
12.  10414 Deepak 2 ½ MC 4 Days Good 
13.  11388 Sugumar 2 ½ MC 7 Days Good 
14.  28680 Siva 1 ¼ MC 3 Days Good 
15.  12934 Joswa 5MC 8 Days Good 
16.  1861 Srinithi 7FC 5 Days Good 
17.  17787 Ajay Aravind 3MC 5 Days Good 
18.  20454 Dalphin 8MC 4 Days Good 
19.  23443 Karthik Kumar 4MC 6 Days Good 
20.  24072 Gowtham 3 ¼ MC 3 Days Good 
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Case reports of twenty cases for the disease – Suram. 
Post graduate department of Kuzhanthai Maruthuvam. 
Sl.N
o. 
IP No. 
Name of the 
Patient 
Age / 
Sex 
Date of 
Admission 
Signs and Symptoms 
Date of 
Discharg
e 
Duration 
of 
disease 
Total no of 
days 
treated 
Result 
IP OP 
1.  55 Shahul 
hameed 
5MC 11.01.16 
Increased Temperature, headache, Cough with 
expectoration 
19.01.16 7 days 9 3 Good 
2.  180 
Petchiammal 7FC 25.01.16 
Increased Temperature, pain in both knee 
joint, All small joint, cold, throat pain 
03.02.16 15 days 10 5 Good 
3.  212 
Tharani 5MC 28.01.16 
Increased temperature., Running nose, 
sneezing, abscess in right gluteal region 
03.02.16 3 days 7 3 
Moder
ate 
4.  401 
Yogamuthu 8MC 05.03.16 
Increased Temperature. Cough with 
expectoration, headache 
08.03.16 1 days 4 3 Good 
5.  627 Charupriya 2FC 08.03.16 Increased Temperature  Nasal discharge 11.03.16 2days 4 3 Good 
6.  769 
Harish 2MC 22.03.16 
Increased Temperature  cough, burning 
micturition 
28.03.16 4 days 7 3 Good 
7.  912 
Ashwin 4MC 03.04.16 
Increased Temperature. throatpain, cervical 
lymphnode enlargement 
09.04.16 2 days 7 3 Good 
8.  1154 Harini 3FC 02.06.16 Increased Temperature, cough  with  04.06.16 3 days 3 7 Good 
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expectoration   
 
9.  1320 
Ananthi 5FC 19.05.16 
Increased Temperature  Nasal discharge, 
throat pain 
25.05.16 2 days 7 2 Good 
10.  1330 Ananthasing
am 
6MC 20.05.16 
Increased Temperature Suprapublic pain, 
burning micturition 
25.05.16 3 days 6 2 Fair 
11.  1353 
Karthick 4MC 23.05.16 
Increased Temperature Cough with 
expectoration, mild wheezing 
29.05.16 2 days 7 1 
Good 
 
 
12.  1356 Sathvika 5FC 23.05.16 Increased Temperature ,Nasal discharge 27.05.16 1days 5 2 Good 
13.  1387 
Anu 10FC 26.05.16 
Increased Temperature ,headache, vomiting, 
cough with expectoration 
31.05.16 1 days 6 1 Good 
14.  1395 
Hari Krishna 4FC 31.06.16 
Increased Temperature cough with  
expectoration 
06.06.16 2 days 4 3 Good 
15.  1467 
Kalai 
12M
C 
28.05.16 Increased Temperature Body pain, Tiredness 31.05.16 1 days 4 3 Good 
16.  1520 
Yaasmeen 6FC 10.06.15 
Increased Temperature mild cough, Nasal 
discharge 
14.06.16 2 days 5 2 Good 
17.  1544 
Vidhubala 10FC 14.06.16 
Increased Temperature Tiredness, cough with 
expectoration 
17.06.16 1 days 4 3 Good 
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18.  1550 
Gayathri 6FC 14.06.16 
Increased Temperature Nasal discharge 
earache 
17.06.16 2 days 4 3 Good 
19.  1551 
Midhun 7MC 14.06.16 
Increased Temperature Nasal discharge sore 
throat 
17.06.16 1 days 4 3 Good 
20.  1560 Vaishali 5FC 15.06.16 Increased Temperature mild cough, head ache 20.06.16 2days 6 2 Good 
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URINE, MOTION, WIDTAL TEST 
Sl. No. IP No. 
Urine Analysis Motion Analysis 
Widal 
test 
Before Treatment After Treatment Before Treatment After Treatment 
Alb Sug 
Dep / 
HPF 
Alb Sug Dep / HPF 
Ova 
Cyst 
Occult 
Blood 
Ova 
Cyst 
Occult 
Blood 
1.  55 – – – – – – – – – – – 
2.  180 – – – – – – – – – – – 
3.  212 – – – – – – – – – – – 
4.  401 – – – – – – – – – – – 
5.  627 – – – – – – – – – – – 
6.  769 – – 3 – 5 PC – – – – – – – – 
7.  912 – – – – – – – – – – – 
8.  1154 – – – – – – – – – – – 
9.  1320 – – – – – – – – – – – 
10.  1330 – – 2 – 3 PC – – – – – – – – 
11.  1353 – – 2 – 3 EC – – – – – – – – 
12.  1356 – – – – – – – – – – – 
13.  1387 – – – – – – – – – – – 
14.  1395 – – – – – – – – – – – 
15.  1467 – – – – – – – – – – – 
16.  1520 – – – – – – – – – – – 
17.  1544 – – – – – – – – – – – 
18.  1550 – – – – – – – – – – – 
19.  1551 – – – – – – – – – – – 
20.  1560 – – – – – – – – – – – 
 
PC – Pus cells  HPF – High Power Field EC – Epithelial Cells 
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l. 
no. 
IP 
No. 
Name of the 
Patient 
Age / 
Sex 
WBC total 
count / cu.mm 
Haematological Investigation   
WBC differential count ESR – 
mm/hr 
Hb – gm% 
ASO Titre 
BT AT   
BT AT P% L% E% P% L% E% BT AT BT AT BT AT 
1.  55 Shahul hameed 5MC 8700 8600 40 56 4 50 48 2 16 10 9.7 9.5 - - 
2.  180 Petchiammal 7FC 5700 8100 54 32 14 59 31 10 95 22 9.9 10.4 468.9 200 
3.  212 Tharani 5MC 8000 8600 62 36 2 64 36 0 16 9 5.5 6.0 - - 
4.  401 Yogamuthu 8MC 6000 6100 60 37 3 62 36 2 40 20 10.5 11 - - 
5.  627 Charupriya 2FC 9600 9700 49 46 5 59 36 5 24 10 10.5 10.8 - - 
6.  769 Harish 2MC 9500 9450 54 42 4 57 39 4 8 8 9.2 9.2 - - 
7.  912 Ashwin 4MC 6700 6900 65 31 4 65 33 2 25 10 9.6 9.6 - - 
8.  1154 Harini 3FC 9400 9500 55 31 14 59 33 8 4 4 9.5 9.2 - - 
9.  1320 Ananthi 5FC 9500 9500 54 42 4 56 43 1 5 4 9 9.8 - - 
10.  1330 Ananthasingam 6MC 7800 7700 55 32 13 59 34 7 50 30 10 10.3 - - 
11.  1353 Karthick 4MC 8500 8700 57 39 4 60 39 1 30 20 10.8 11.2 - - 
12.  1356 Sathvika 5FC 8000 8100 53 35 12 59 39 2 10 8 12 12.1 - - 
13.  1387 Anu 10FC 9100 9000 60 31 9 63 30 7 18 6 11 11 - - 
14.  1395 Hari Krishna 12M
C 
8200 8200 45 37 18 52 36 12 22 10 9.8 10 
- - 
15.  1467 Kalai 4FC 8300 8100 55 42 3 59 38 3 12 8 10.5 10.8 - - 
16.  1520 Yaasmeen 6FC 7000 7000 62 28 10 70 24 6 32 12 9.9 10.2 - - 
17.  1544 Vidhubala 10FC 9300 9500 54 38 8 59 34 7 35 30 10.5 10.5 - - 
18.  1550 Gayathri 6FC 8950 9100 52 46 2 58 41 1 9 8 11 11 - - 
19.  1551 Midhun 7MC 9500 9000 46 40 14 52 40 8 10 10 9.5 9.5 - - 
20.  1560 Vaishali 5FC 9200 9200 62 30 8 61 35 4 40 20 9 10.1 - - 
BT – Before Treatment, AT – After Treatment, P – Polymorphs, L-Lymphocytes, E-Esinophils, ESR-Erythrocyte Sedimentation Rate , Hb- 
Hemoglobin, ASO-Anti –Streptolysin O-Titre 
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Discussion 
 
Around 4448 kind of diseases explained in siddha system, in that “suram” is 
also kind of a disease. The disease “suram” is noted by YUGI MUNI as “king of 
all diseases”. 
Although in siddha pediatric books “suram” is classified in various types, 
here the author selected it as in one heading. Suram is a clinical entity described by 
siddhars and it has clinical features such as increased temperature,headache, 
cough,loss of appetite,nasal discharge,etc… The clinical features of suram have 
been furnished by some of the siddha literatures  
Like Balavagadam, pillaippinimaruthuvam etc. 
For the study on suram the author selected 20 OP and 20 IP patients and 
were treated in the PG kuzhanthai maruthuvam department, Government siddha 
medical college, palayamkottai.as in patients a case record based on siddha and 
modern aspect was prepared and maintained for each patient. 
For the diagnostic purpose the parameter used in siddha aspect 
poriyalarithal, pulanalarithal, vinaathal, uyirthathukkal,udalthaathukkal and 
neikkuri. The modern parameters used were criteria for the suram and lab 
investigations. 
I. Biochemical analysis 
 The result of biochemical analysis of   “ vettumarankuligai” shows 
that it consists of calcium,sulphate,chloride,ferric iron,ferrous iron,saturation 
compound and amino acid. 
II. Pharmacological studies 
 The pharmacological studies shows that the trial drug 
“vettumarankuligai” possess significant anti-pyretic and anti-inflammatory action. 
III. Acute toxicity study 
 The acute toxicity study shows that the trial drug has not produce 
any toxic effect. The acute toxic study in duly attached with the experiment. 
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IV. Anti-microbial study 
 The anti- microbial study of the trial drug shows sensitivity to 
staphylococcusaureus and  Escherichiacoli bacteria. 
V. Clinical trial 
1. Age distribution 
Among the 40 cases, 10 cases in the age group between 1-3 yrs., 17 cases in 
3-6 yrs.,and 13 cases in 6-12 yrs. 
2. Sex distribution 
Out of the 40 patients studied 25 cases were male children (62.5%) and 15 
cases (37.5%) were female children. 
3. Religion distribution 
Among the 40 cases 85% were Hindu, 10 % were Christian and 5% were 
Muslim. 
4. Socio-economic status 
Out of the 40 cases 65% were poor and 25% were middle class and 10% 
were rich. 
5. Dietary habits 
90% cases have mixed diet. 
10% of cases were vegetarian diet. 
6.  Paruvakaalangal 
Among the 40 cases selected 37.5% seemed to affected in Munpani 
kaalam,30% cases were affected in Pinpani kaalam,32.5% cases were 
affected in Elavenilkaalam. 
7.  Thinai reference 
Total 40 cases were belong to maruthanilam. The selected cases were from 
Tirunelveli Dt.Tirunelveli  is a marutham type of land. According to our 
siddha text, the people who are living in marutham typeof land have not 
affected by disease, but today’s habitual changes cause diseases. 
 
 
 
90 
 
6. Uyirthaathukkal 
a) Derangements of vatham 
Among the ten types of vatham, other than Nagan and Thananjayan 
all are affected in suram. 
Pranan deranged in 50% of patients, it causes breathing difficulties and 
poor appetite. Abanan deranged in 7.5% patients it causes constipation and 
reduced frequency of urine output. 
In 75% of case Samanan deranged along with other kuttrams it produce 
poor appetite and indigestion. Uthanan deranged in 32.5% of cases,it causes 
gradual emaciation and hoarseness of voice. 
Viyanan deranged in 100% of cases because of its spreading nature,it 
spreads heat from stomach to all over the body and increased body temperature. 
In 10% patient koorman and in 32.5% patient kirukaran were 
affected,they both causes cough, running nose and poor appetite. 
Devathathan  deranged in 25% of patients it is responsible for laziness, 
which cause sleepiness. 
b) Derangement of pitham 
Derangement of pitham in suram causes poor appetite, disability to do 
daily activities. 
In 75% of patients anal pitham deranged which is accountable for 
digestion.it derangement causes poor appetite. Ranjagam deranged in 50% of 
cases.Saathagam  deranged in 25% cases lag of concentration and so produce 
fatigue. 
c) Derangement of  kabam 
Avalambagam deranged in 50% cases. Avalambagam  is located in lungs. 
In unbalanced stage it may cause breathing difficulties and cough. 
Kilathegam deranged in 75% of patients.It causes indigestion and poor 
appetite. 
Tharpagam deranged in 10% cases ,It  causes burning sensation in eyes 
and redness of eyes. 
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Santhegam deranged in 2.5% cases.Santhegam has given protection to the 
joints. When it is going in trouble it produce joints pain. 
7. Udalthaathukkal 
In ezhuudarthaathukkalSaram affected in 75% patients .The derangement of 
saaram and senneer produce general disability and easy fatiguability.Senneer 
affected in 50% patients ,due to nutritional impairment. In 25% cases oon were 
affected.kozhuppu affected in 20% of cases due to gradual emaciation. 
8. Envagaitheervugal 
In envagaithervugal fever and sweating was observed by sparism,it 
deranged in 100% patients.coated tongue and dryness of the tongue  
observed by naa, it affected in 20% of cases. Red colour pale colour 
conjunctiva and nail buds are observed  by niram,it affected in 10% 
cases.Hoarseness of voice observed in 5% of patients.vizhi affected in 15% 
and malam affected in 5% cases.Naadi was observed in all 40 
cases.Siruneer affected in 20% cases. 
9)  Neikkuri 
In urine examination of  all 20 patients  6 cases spreads like snake, in 4 
cases spread like ring and in 10 cases spread like pearl. 
All the drugs were put to therapeutic and only after purification process laid 
down for them individually no toxic or side effects were clinical and reportedly 
observed in any case during the course of treatment. 
Treat the suram and its clinical features with the trial drug 
“vettumarankuligai”internally had properties of drugs possess kaarppusuvai and 
ushnaveeriyam. It acts on the increased kabam in  the stomach and relieves” 
aamam”, the toxin. And it preserves” agni “in stomach . By this way the drug 
removes the root cause of  the disease  suram. 
The author selected the drugs had anti -bacterial, anti-pyretic and anti-
inflammatory agents proved by biochemical analysis and pharmacological 
studies.so the trial drug is effective and suitable for curing suram and its 
symptoms .All the drugs are easily available. In this study the herbal drugs also 
have the satisfactory prognosis on suram and its symptoms have been proved. 
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From all the above observation and results it is clear that out of  40 cases 90% 
showed  significant improvement,and 10 % cases  showed moderate 
improvement.Therfore the selected drug “vettumarankuligai” produced good 
effect in reduced the signs and symptoms of  suram.  
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Summary 
  The study of the ‘suram’ is done to find out a complete relief to those 
affected , with a herbo-mineral combination,vettumarankuligai. 
 Various literature evidence relavant to suram were collected from both 
siddha system as well as modern system of medicine. 
 40 patients from both sexes of different age groups, were selected and 
diagnosis was made on both the siddha and  modern methodology.The patients 
were treated with “vettumarankuligai” iternally  in the In patients ward of  PG 
Kuzhanthai maruthuvam department and also in out patient department.Further 
follow up of the cases were also considered for the prognosis of the patient was 
followed and the proforma was prepared accordingly. 
 The efficacies of the trial drug “ vettumarankuligai” was studied and 
observed during the study.These analysis ensure the efficacies of the drug were 
proved clinically. 
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Conclusion 
 The author has been  selected dissertation topic were well analyzed on the 
siddha and modern parameters. 
 The points were thoroughly examined with clinical and biochemical analysis. 
 All the cases were treated with”vettumarankuligai”. 
 Clinical results were found to be satisfactory. 
 The medicine was free from adverse effects, clinically. 
 So it is concluded suram and its symptoms could be  well treated and 
observed by a good medicine”vettumarankuligai“.It briefs the suram in 
various origin along with diet restriction stated in siddha literature. 
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BIO-CHEMICAL ANALYSIS OF VETTUMARAN KULIGAI 
Preparation of the extract:  
 100 mg of the drug is weighed accurately and placed into a clean beaker 
and added a few drops of concentrated Hcl and evaporated it well. After 
evaporation cooled the container and added a few drops of concentrated nitric acid 
evaporated it well. After cooling the content add 20ml of distilled water and 
dissolved it well. Then it is transferred to 100 ml volumetric flask and made up to 
100 ml with distilled water mix well. Filter it, then it is taken for analysis. 
QUALITATIVE ANALYSIS 
S.NO. EXPERIMENT OBSERVATION INFERENCE 
1.  TEST FOR CALCIUM 
2ml of the above prepared 
extract is taken in a clean 
test tube. To this add 2ml of 
4% Ammonium oxalate 
solution 
A white 
precipitate  is 
formed 
Indicates the 
presence of 
calcium  
2. TEST FOR SULPHATE 
2ml of the extract is added 
to 5% Barium chloride 
solution. 
A white 
precipitate  is 
formed 
Indicates the 
presence of 
sulphate 
3.  TEST FOR CHLORIDE 
The extract is treated with 
silver nitrate solution 
A white 
precipitate  is 
formed 
Indicates the 
presence of 
chloride 
4. TEST FOR 
CARBONATE 
The substance is treated 
with concentrated Hcl. 
No brisk 
effervescences is 
formed   
Absence of 
carbonate 
5. TEST FOR STARCH 
The extract is added with 
weak iodine solution 
No blue colour is  
formed 
Absence of starch 
103 
 
6.  TEST FOR FERRIC 
IRON 
The extract is acidified with 
Glacial acetic acid and 
potassium ferro cyanide. 
Blue colour is 
formed 
Indicates the 
presence of ferric  
iron  
7. TEST FOR FERROUS 
IRON  
The extract is treated with 
concentrated Nitric acid and 
Ammonium thiocyanate 
solution 
Blood red colour 
is formed 
Indicates the 
presence of 
ferrous iron 
8.  TEST FOR PHOSPHATE 
The extract is treated with 
Ammonium Molybdate and 
concentrated nitric acid 
No yellow  
precipitate is 
formed 
Absence of 
phosphate 
9.  TEST FOR ALBUMIN 
The extract is treated with 
Esbach’s reagent 
No yellow  
precipitate is 
formed 
Absence of 
albumin  
10.  TEST FOR TANNIC 
ACID 
The extract is treated with 
ferric chloride. 
No Blue black 
precipitate is 
formed 
Absence of tannic 
acid 
11.  TEST FOR 
UNSATURATION 
Potassium permanganate 
solution is added to the 
extract 
It gets 
decolourised  
Indicates the 
presence of an 
saturation 
compound 
12.  TEST FOR THE 
REDUCING SUGAR 
5ml of Benedict’s 
No colour change 
occurs 
Absence of 
reducing sugar 
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qualitative solution is taken 
in a test tube and allowed to 
boil for 2 minutes and add 
8-10 drops of the extract 
and again boil it for 2 
minutes. 
13.  TEST FOR AMINO 
ACID 
One or two drops of the 
extract is placed on a filter 
paper and dried well. After 
drying, 1% Ninhydrin is 
sprayed over the same and 
dried it well. 
Violet colour is 
formed  
Indicates the 
presence of amino 
acid 
14. TEST FOR ZINC 
The extract is treated with 
Potassium Ferrocyanide. 
No white 
precipitate is 
formed 
Absence of zinc 
 
Inference: 
 The above analysis indicates presence of calcium, sulphate, 
chloride, ferric iron, ferrous iron, saturation compound and amino acid. 
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ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF  
VETTUMARAN KULIGAI 
OBJECTIVES 
The aim of this Study is to evaluate the toxicity of the test substance 
VETTUMARAN KULIGAI, when administered orally to Female Wister Rats with 
different doses, so as to provide a rational base for the evaluation of the 
toxicological risk to man and indicate potential target organs. 
Guidelines followed: 
(a)  OECD Guidelines No. 423, 
Study Design and Controls: 
1) Female Wister Rats in controlled age and body weight were selected. 
2) VETTUMARAN KULIGAI was administered at 5  mg/kg, 50  mg/kg, 300  
mg/kg, 1000  mg/kg, and   
   2000  mg/kg body weight as  (Water) as suspension along with blank. 
3) The results were recorded on day 0, with single oral dosing period of 14 days.  
 
EXPERIMENTAL PROCEDURE 
1. ANIMALS  
1.1. Supply 
        A total of 15 Female Wister Rats with an approximate age of 6 weeks and 
purchased from M/s.Venkateshwara Enterprises Pvt. Ltd, Bangalore. On their 
arrival a sample of animals was chosen at random and weighed to ensure 
compliance with the age requested. The mean weights of Female Wister Rats were 
100-150 g respectively.  The animals were housed in metabolic cages (55 x 32.7 x 
19 cm), with sawdust litter, in such a way that each cage contained a maximum of 
3 animals of the same sex. 
All animals underwent a period of 20 days of observation and 
acclimatization between the date of arrival and the start of treatment. During the 
course of this period, the animals were inspected by a veterinary surgeon to ensure 
that they fulfilled the health requirements necessary for initiation of the Study. 
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1.3. Housing 
The Female Wister Rats were housed in metabolic cages (55 x 32.7 x 19 
cm), placed on racks. From the week before initiation of the treatment, each cage 
contained a maximum of 6 mice of the same sex and treatment group. 
Each cage was identified by a card, color coded according to the dose level. 
This card stated the cage number, number and sex of the animals it contained, 
Study number, test substance code, administration route, dose level and Study 
Director's name, date of the arrival of the animals and initiation of treatment. 
The temperature and relative humidity were continuously monitored. 
Lighting was controlled to supply 12 hours of light (7:00 to 19:00 hours) and 12 
hours of dark for each 24-hour period. 
The cages corresponding to each experimental group were distributed on 
racks in such a manner that external factors, such as environmental conditions, 
were balanced as far as possible. 
2. DIET 
   All the rats had free access to a pelleted rat diet. The diet was analyzed by 
the   manufacturer to check its composition and to detect possible contaminants. 
2.1. Water 
The water was offered ad libitum in bottles.  
3. ADMINISTRATION ROUTE AND PROCEDURE 
          The test substance was administered orally. The Female Wister Rats 
belonging to the control group were treated with the vehicle (Water) at the same 
administration volume as the rest of the treatment groups. 
3.1 Numbering and Identification 
The animals were marked on body with picric acid solution prepared in 
water. The marking within the cage was as below. 
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Table-1 Numbering and Identification 
 
 
                            
 
 
The group no., cage no., sex of the animal and animal no. were identified as 
indicated below using cage label and body marking on the animals 
Table-2 Numbering and Identification 
 
3.2 Doses 
The doses for the study were selected based on literature search and range 
finding study. Following the period of fasting, the animals were weighed and then 
drug was administered orally as single dose using a needle fitted onto a disposable 
syringe of approximate size at the following different doses. 
                                                    Table-3 Doses 
                   GROUP DOSE 
 
GROUP DOSE 
Group-I 5  mg/kg 
Group-II 50  mg/kg 
Group-III 300  mg/kg 
Group-IV 1000  mg/kg 
Group-V 2000  mg/kg 
Group No Animal Marking 
1 Head 
2 Body 
3 Tail 
Cage No Group No Animal Marking Sex 
1 I H,B,T Female 
2 II H,B,T Female 
3 III H,B,T Female 
4 IV H,B,T Female 
5 V H,B,T Female 
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The test item was administered as single dose. After single dose 
administration period, all animals were observed for day 14. 
Dose Preparation 
VETTUMARAN KULIGAI was added in distilled water and completely 
dissolved to form oral for administration. The dose was prepared of a required 
concentration before dosing by dissolving, in distilled water. It was mixed well. 
The preparation for different doses was vary in concentrations to allow a constant 
dosage volume. 
3.3 Administration 
The test item was administered orally to each Female Wister rats as single 
dose using a needle fitted onto a disposable syringe of appropriate size at the 
following different doses. The concentration was adjusted according to its body 
weight. The volume was not exceeding 10 ml/kg bodyweight. Variability in test 
volume was minimized by adjusting the concentration to ensure a constant volume 
at all dose levels. 
3.4 Observation period 
All animals were observed for any abnormal clinical signs and behavioral 
changes. The appearance, change and disappearance of these clinical signs, if any, 
were recorded for approximately 1.0, 3.0 and 4.0 hours post-dose on day of dosing 
and once daily thereafter for14 days. Animals in pain or showing severe signs of 
distress were humanely killed. The cageside observation was included changes in 
skin, fur, eyes and mucous membranes, occurrence of secretions and excretions. 
Autonomic activity like lacrimation,  piloerection, pupil size and unusual 
respiratory pattern, changes in gait, posture, response to handling, presence of 
clonic or tonic movements, stereotypes like excessive grooming and repetitive 
circling or bizarre behavior like self-mutilation, walking backwards etc were 
observed. At the 14th day, sensory reactivity to stimuli of different types (e.g. 
auditory, visual and proprioceptive stimuli) was conducted. Auditory stimuli 
responses were measured by clicker sound from approximately 30 cm to the rats; 
visual stimuli response were measured with the help of shining pen light in the eye 
of rats and placing a blunt object near to the eye of rats. Response to 
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proprioceptive stimuli was measured by placing anterior/dorsal surface of animals 
paw to the table edge. The responses of reactions for these three exercises were 
normal in animals belonging to both the controls as well as drug treatment dose 
groups. 
4 Mortality and Morbidity 
All animals were observed daily once for mortality and morbidity at 
approximately 1.0, 3.0 and 4.0 hours post dose on day of dosing and twice daily 
(morning and afternoon) thereafter for 14 days. 
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EVALUATION OF ACUTE TOXICITY OF VETTUMARAN 
KULIGAI 
 Effect of Acute Toxicity (14 Days) of VETLUMARAN KULIGAI 
Table: Shows Physical and behavioral examinations. 
  RESULT    Table –1 Physical and behavioral examinations. 
Group no. Dose(mg/kg Observation sign No. of animal affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
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Table-5 Home cage activity 
Functional and 
Behavioural 
observation 
Observation 5mg/kg 
Group 
(G-I) 
50mg/kg 
(G-II) 
300mg/kg 
(G-III) 
 
1000mg/kg 
(G-IV) 
2000mg/kg 
(G-V) 
Female n=3 Female 
n=3 
Female 
n=3 
Female n=3 Female n=3 
Body position Normal 3 3 3 3 3 
Respiration Normal 3 3 3 3 3 
Clonic involuntary 
Movement 
Normal 3 3 3 3 3 
Tonic involuntary 
Movement 
Normal 3 3 3 3 3 
Palpebral closure Normal 3 3 3 3 3 
Approach response Normal 3 3 3 3 3 
Touch response Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Pinna reflex Normal 3 3 3 3 3 
Tail pinch response Normal 3 3 3 3 3 
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 Table-6 Hand held observation 
Functional and 
Behavioral observation 
Observation Control 5 mg/ 
kg  
(G-I) 
50 
mg/kg 
(G-II) 
300mg
/kg 
(G-III) 
1000mg/kg 
(G-IV) 
2000mg/kg 
(G-V) 
Female 
n=3 
Femal
e n=3 
Femal
e n=3 
Femal
e n=3 
Female 
n=3 
Female n=3 
Reactivity Normal 3 3 3 3 3 3 
Handling Normal 3 3 3 3 3 3 
Palpebral closure Normal 3 3 3 3 3 3 
Lacrimation Normal 3 3 3 3 3 3 
Salivation Normal 3 3 3 3 3 3 
Piloerection Normal 3 3 3 3 3 3 
Pupillary reflex Normal 3 3 3 3 3 3 
Abdominal tone Normal 3 3 3 3 3 3 
Limb tone Normal 3 3 3 3 3 3 
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Table-7 Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
 
Result: 
From acute toxicity study it was observed that the administration of 
VETTUMARAN KULIGAI at a dose of 2000mg/kg, to a rats. From acute toxicity 
study it was observed that the administration of VETTUMARAN KULIGAI at a dose 
of 2000 mg/kg to the rats do not produce drug-related toxicity and mortality. So No-
Observed-Adverse-Effect- Level (NOAEL) of VETTUMARAN KULIGAI is 2000 
mg/kg. 
5.0 DISCUSSION 
VETTUMARAN KULIGAI was administered single time at the dose of 
5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for 
consecutive 14 days after administration. Doses were selected based on the pilot study 
and literature review. All animals were observed daily once for any abnormal clinical 
signs. Weekly body weight and food consumption were recorded. No mortality was 
observed during the entire period of the study. Data obtained in this study indicated no 
significance physical and behavioural signs of any toxicity due to administration of 
VETTUMARAN KULIGAI at the doses of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg 
and 2000mg/kg to rats.  
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand held 
activity were observed. Home cage activities like Body position, Respiration, Clonic 
involuntary movement, Tonic involuntary movement, Palpebral closure, Approach 
response, Touch response, Pinna reflex, Sound responses, Tail pinch response were 
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observed. Handheld activities like Reactivity, Handling, Palpebral closure, 
Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominaltone, Limb tone 
were observed. Functional and behavioral examination was normal in all treated 
groups.Food consumption of all treated animals was found normal as compared to 
normalgroup. 
Body weight at weekly interval was measured to find out the effect of 
VETTUMARAN KULIGAI on the growth rate. Body weight change in drug treated 
animals was found normal. 
6.0 SUMMARY & CONCLUSION: 
Summary: 
The present study was conducted to know single dose toxicity of 
VETTUMARAN KULIGAI on female wister rats. The study was conducted using 15 
female Wister rats. The female animals were selected for study of 8- 12 weeks old 
with weight range of within ± 20 % of mean body weight at the time of 
randomisation. The groups were numbered as group I, II, III, IV and V and dose with 
5mg/kg, 50mg/kg, 300mg/kg, 1000mg/kg and 2000mg/kg of VETTUMARAN 
KULIGAI. The drug was administered by oral route single time and observed for 14 
days. Daily the animals were observed for clinical signs and mortality. Body weight of 
all animals was recorded once in a week. 
There were no physical and behavioral changes observed in albino mice of 
5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats during 14 days. 
Body weight of all animals did not reveal any significant change as compared 
to vehicle control group. 
Food consumption of all group animals was normal. 
Mortality was not observed in any treatment groups. 
Conclusion: 
The study shows that VETTUMARAN KULIGAI did not produce any toxic 
effect at dose of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats. So 
No-Observed-Adverse-Effect-Level (NOAEL) of VETTUMARAN KULIGAI is 2000 
mg/kg. 
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7.0 ABBREVIATIONS 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o  peros 
ML  Milliliter 
%   percentage 
R&D   Research and Development 
EDTA  Ethylene Diamine Tetra Acetic Acid 
M   Male 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments 
on 
Animals 
8.0 REFERENCES 
 Schedule –Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
 OECD 2001- Guideline on Sub-Acute Oral Toxicity (AOT). Environmental 
health & 
Safety monograph series on testing and adjustment No. 407. 
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Evaluation of antipyretic activity of Vettumarankuligai in yeast induced pyrexia 
.Introduction 
The practice of herbal medicine dates back to the very earliest period of known 
human history. There is evidence of herbs have been used in the treatment of diseases 
and for revitalizing body system in almost all ancient civilization. Ayurveda and 
siddha the ancient healing systems have provided a rational basis for treatment of 
various ailments. Pain, inflammation and fever are very common complications in 
human beings.  
Pyrexia or fever is caused as a secondary impact of infection, malignancy or 
other diseased states; wherein there is abrupt increase the core temperature above the 
normal level (Math et al., 2011). It is the body’s natural defence to create an 
environment where infectious agent or damaged tissue cannot survive 
(Chattopadhyayet al.,2005).  
Normally the infected or damaged tissue initiates the enhanced formation of 
pro-inflammatory mediator’s (cytokines like interleukin 1a and TNF- a) which 
increase the synthesis of prostaglandin E2 (PGE2) near peptic hypothalamus area and 
thereby triggering the hypothalamus to elevate the body temperature (Spacer and 
Breder, 1994).The regulation of body temperature requires a delicate balance between 
the production and loss of heat.  
As the temperature regulatory system is governed by a nervous feedback 
mechanism, so when body temperature becomes very high, it dilates the blood vessels 
and increase sweating to reduce the temperature; but when the body temperature 
becomes very low hypothalamus protect the internal temperature by vasoconstriction.  
The hypothalamus regulates the set point at which body temperature is 
maintained. In fever this set point is elevated and a drug like paracetamol does not 
influence body temperature when it is elevated by factors such as exercise or an 
increase in ambient temperature (Ashokkumaret al., 2010). 
 
Several plants and their products are claimed and proved to possess antipyretic 
property (Nanda et al., 2009). Although the body surface temperature is ordinarily 
measured in clinical practice, it is the body core temperature which is physiologically 
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important. The rectal temperature (which reflects the core temperature closely) is 
about 0.6ºC higher than oral temperature and about 1.4ºC higher than axillary 
temperature.  
The generally accepted normal limits of rectal temperature in adults are 36.1ºC 
and 37.8ºC; the body temperature is higher in infants. If the core temperature rises by 
more than a few degrees in man, mental changes occur. It is well known that an 
individual with high fever is often confused and delirious. The working of many tissue 
enzymes is also adversely affected and hyperpyrexia may result in death. However, 
core temperature below 40.5ºC is generally tolerated by most individuals (Satoskaret 
al., 2010).  
A natural antipyretic agent with reduced or non- toxicity is essential. Further, 
as health care costs continue to escalate,  the attraction for low cost remedies has 
stimulated consumers to re-evaluate the potential of alternatives (Chattopadhyay and 
Arunachalam, 2005; Valarmathiet al.. 2010; Jaiswalet al., 2011). Therefore the 
present study was undertaken to investigate the antipyretic properties of 
theVettumarankuligai. 
REQUIREMENTS: 
Animal Wistar albino rats weighing about 180-200g 
Drugs and chemicals          : Injection of 20 % w/v of brewer’s yeast (10ml/kg)                  
Vettumarankuligai. 
Experimental animals  
Wistar albino rats were weighed (180-200 g) were procured from K.M.College 
of Pharmacy,Madurai.. The animals were housed in the departmental animal house 
under standard conditions (26±2°C and relative humidity 30-35%) in 12 hours light 
and 12 hours dark cycle respectively for 1 week before and during the experiments. 
Animals were provided with standard rodent pellet diet and had free excess of water. 
 The composition of diet is 10% protein, 4% Arachisoil, 1% fibers, 1% 
calcium, 1000 IU/gm vitamin A and 500 IU/gm vitamin D. All the animals were 
acclimatized to the laboratory conditions prior to experimentation. All the experiments 
were conducted between 10.00 and 17.00hr and were in accordance with the ethical 
guidelines of the CPCSEA.. 
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TREATMENT PROTOCOL: 
Body weights of the animals were recorded and they were randomly divided 
into 5groups of 6 animals each as follows: 
 Group I: Animals served as control normalsaline 10 ml/kg) 
  
Group II : Animals were treated with yeast via subcutaneous injection (10ml/kg).  
 
Group III :Animals were administered with yeast (10 mL/kg) and the standard drug 
paracetamol150mg/kg b.w.), orally  
 
Group IV :Animals were administered with yeast (10mL/kg,) andreceived 200mg/kg 
of Vaettumaarankuligaidissolved with 2ml sterile water and administered through 
orally. 
Group-VAnimals were administered with yeast (10 mL/kg,) and received 400mg/kg 
of Vaettumaarankuligai dissolved with 2ml sterile water and administered through 
orally. 
Antipyretic activity 
Yeast induced pyrexia method  
A suspension of Brewer’s yeast (15%) in saline (0.9%) was prepared. 
Fivegroups, each containing 6 rats of either sex were taken. The thermocouple was 
inserted 2cm deep into the rectum and the rectal temperatures were recorded. Pyrexia 
was induced by subcutaneous injection of 20% w/v of brewer’s yeast (10 ml/kg) in 
distilled water. The basal rectal temperature was measured before the injection of 
yeast, by inserting digital clinical thermometer to a depth of 2 cm into the rectum. The 
sight of injection was massaged in order to spread the suspension beneath the skin.  
The room temperature was kept at 22-24°C, immediately after yeast 
administration, food was withdrawn and the rise in rectal temperature was recorded. 
The measurement was repeated after 30 minutes. The dose of the test compound and 
standard drug was given orally. The rectal temperature was recorded again after 1, 2 
and 4 hours. Paracetamol (150mg/kg) was selected as a standard drug. The 
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Vettumarankuligai were dissolved in sterile water. The data were analyzed for 
significance using the one way anova followed by newmannkeuls multiple range tests. 
Results 
The antipyretic potential of Vettumarankuligai was evaluated by determining 
its effect on yeast-induced pyrexia in albino rats. Table.1 shows that animals treated 
with Vettumarankuligai possess significant antipyretic property when compared with 
group 2 and also provided the highest marked antipyretic activities. The result showed 
the Vettumarankuligai at a dose of 200 and 400 mg/kgcaused lowering of the body 
temperature induced by injection of Brewer s yeast in the experimental animals 
significantly from 1 to 3 hrs following its administration.   
The effect of Vettumarankuligai on yeast-induced pyrexia showed that the 
rectal temperature was markedly elevated to 39.19°C, 3 hr after the subcutaneous 
injection of yeast suspension,decreased to 38.67°C within 3hr of Vettumarankuligai 
treatment respectively, and reduced till 3hrs showing a sizeable decrease and was 
comparable to paracetamol at 150 mg/kg marked antipyretic activity detected which 
were significantly different than the controls (p<0.01). The antipyretic activity was 
equal to that of the standard drug paracetamol.  
This result reveals that the Vettumarankuligai has marked antipyretic activity 
as compared with standard paracetamol.  
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Table.1The Effect of Vettumarankuligai on body temperature in yeast induced 
pyrexia. 
 
Group Recctal Temperature 
0hr 1hr 2hr 3hr 
Group I 
(Control) 
38.32 ± 0.8 37.50 ± 0.75 37.70 ± 0.85 37.55 ± 0.48 
Group II(10 
ml/kg) 
41.48 ± 0.23 42.18 ± 0.20 39.30 ± 0.17 39.17 ± 0.25 
Group 
III(150 
mg/kg) 
41.32 ± 0.19 39.60 ± 0.22 38.50 ± 
0.25* 
37.58 ± 0.40 * 
Group 
IV(200 
m/kg) 
41.55 ± 0.02 39.78 ±0.25 39.25 ± 
0.20* 
38.60 ± 0.38 * 
 
 
Group V                  
(400 m/kg) 
41.30 ± 0.04 39.45 ±0.18 39.12 ± 
0.20* 
38.55 ± 0.40 * 
 
 
 
Values are expressed as Mean ±SEM. n = 6 in each group,  
 
*values are significant(P < 0.01) different from pyrexia control (G2) 
 
Discussion 
The Vettumarankuligai showed significant antipyretic activity. The animals 
were also fevered by injection of Brewer’s yeast suspension (10 mL/kg) 
subcutaneously in back below the nape of the neck for the antipyretic activity. The Vettumarankuligai showed significant decrease in elevated body temperature as 
compared to standard drug paracetamol. 
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 The possible mechanism of antipyretic action may be due to the inhibition of 
prostaglandin as that of paracetamol by blocking the cyclo-oxygenase enzyme activity 
(Chandrasekharan and Simmons, 2004). There are several mediatorsfor pyrexia and 
the inhibition of any one of these can be responsible for the antipyretic effect (Rawlins 
andKarger, 1973). Inhibition of any of these mediators may bring about antipyresis.  
Antipyretics have been shown to suppress fever by inhibiting prostaglandin 
synthetase, resulting in the blockade of the synthesis of prostaglandin in the brain or 
suppressing the rise of interleukin-1α production subsequent to interferon production. 
The oral administration of Vettumarankuligai were significantly attenuated rectal 
temperature of yeast induced pyrexia in rats and comparable to that of standard drug 
paracetamol.  
So, inhibition of prostaglandin synthesis could be the possible mechanism of 
antipyretic action as that of paracetamol.  Also, there are several mediators or 
multiprocesses underlining the pathogenesis of fever.  Inhibition of any of these 
mediators may bring about antipyresis (Akilet al.,1998). Thus, it can be postulated 
that the Vettumaarankuligaicontains pharmacologically active principles that interfere 
with the release of prostaglandins.  
This may be attributed to the presence of the various bioactive compound 
present in the Vettumaarankuligai which may be involved in inhibition of 
prostaglandin synthesis. Also, there are several mediators or multiprocessors 
underlining the pathogenesis of fever. Inhibition of any of these mediators may bring 
about antipyresis. Flavanoids like baicalinhave been shown to exert antipyretic effect 
by suppressing TNF-α (Adesokanet al.,2008) and its related compounds also exhibit 
inhibition of arachidonic acid peroxidation, which results in reduction of 
prostaglandin levels thus reducing the fever and pains (Germainet al., 2011).  
The present study also correlates with the study of Zakariaetal.,(2007) that the 
compounds like flavonoids and saponins are suggested to act synergistically to exert 
the observed pharmacological activity. Flavonoids are known to target prostaglandins 
which are responsible for pyrexia (Rajnarayananet al., 2006). The presence of 
flavonoids in the Vettumarankuligai  may be contributory to its antipyretic activity. 
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This potentiality supports the earlier traditional claims as a pediatric antipyretic 
remedy. 
Conclusion 
Herbal medicines derived from the plant extracts are being increasingly utilized 
to treat a wide variety of clinical diseases, though relatively little knowledge about 
their mode of action is available. In conclusion, the present study provides evidences 
for the Vettumarankuligai shows significant antipyretic activity which could partly 
contribute to its ethnomedical use.  
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ANTI-INFLAMMATORY ACTIVITYOF SIDDHA FORMULATION VETTU 
MARAN KULIGAI 
 
The anti-inflammatory activities of siddha formulation Vettumarankuligai at 
a dose of 200 and 400mg/kg were evaluated using carrageenan-induced paw edema 
method. The inflammation was readily produced in the form of edema with the help of 
irritant such as carrageenan. Carrageenan is a sulphated polysaccharide obtained from 
sea weed (Rhodophyceae) and when injected cause the release of prostaglandins by 
the way it produces inflammation and edema. 
REQUIREMENTS: 
Animal                             : Albino rat (180-200 g) 
Drugs and chemicals          : Carrageenan (1%w/v), Diclofenac sodium (standard), 
Carboxy methyl cellulose (1%w/v), 
Digital plethysmo meter. U G O Basile (Italy) 
Test compounds                : siddha formulationVaettumaarankuligai 
METHOD: 
Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1)The animals were divided into 4 groups each having six animals. A 
freshly prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with the siddha 
formulationVettumarankuligaitest Compounds dissolved with 2 ml sterile water given 
through orally 30 min before the carrageenan treatment. The paw volumes of the test 
compounds, standard and control groups were measured at 60,240,360 minutes of 
carrageenan treatment with the help of Digital plethysmometer (Ugo basile, Italy). 
Mean increase in paw volume was measured and the percentage of inhibition was 
calculated. 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
Vc-mean increase in paw volume in control group of rats. 
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TABLE No.1 
ANTI-INFLAMMATORY ACTIVITY OF SIDDHA FORMULATION VETTU 
MARAN KULIGAI 
Treatment Dose (mg/kg) 
Paw volume(ml) 
as measured by 
mercury 
displacement at 
6 hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 
10ml/kg orally 5.35±0.90 - 
Group II 
Std 
10mg/kg 
I.P.Diclofenac 
sodium 
1.75±0.42 67.36%*a 
Group III 
Vettumarankuligai 
200mg/kg.Orally. 2.10±0.52 60.60%*a 
Group IV 
Vettumarankuligai 
400mg/kg.Orally. 1.95±0.40 63.63%*a 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple 
range tests, to determine the significance of the difference between the control group 
and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
Results 
Anti- inflammatory activity 
Both doses ofsiddha formulationVettumarankuligai at 200mg/kg and 400mg/kg 
were tested for their Anti- inflammatory activity by using carrageenan Induced rat 
paw edema method and the results are tabulated in table no 1.  The results reveals 
that   both doses of siddha formulation vettumarankuligai at 200mg/kg and 
400mg/kgdoses possesses significant Anti- inflammatory activity when compared to 
control group at p<0.01. 
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ANTIMICROBIAL  STUDIES 
AIM 
  To study the Anti-microbial action of   “Vettumaran Kuligai”  done by 
“paperdisc agar diffusion method” – Kirby – bauyer method. 
MEDIUM  
 Muller Hinton agar 
COMPONENTS OF MEDIUM  
 Beef extract   - 300gms/lit 
 Agar    - 17gms/lit 
 Starch    - 1.5gms/lit 
 Casein Hydroxylate - 17.5gms/lit 
 Distilled water  - 1000ml 
 PH    - 7.6 
PROCEDURE 
 The media was prepared from the components and poured and dried on a petri 
dish. The organism was streaked on the medium and the test drug  (1gm drug in 10ml 
water) was placed on the medium. This is incubated at 37   for one over night and 
observed for night and observed for the susceptibility shown up clearance around the 
drug. 
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GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
PG DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
CONSENT FORM 
 
An open clinical study to evaluate the safety and efficacy of Siddha sasthric 
formulation “ VettumaranKuligai” for the management of Suram. 
CERTIFICATE BY INVESTIGATOR  
I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent 
Date  : Signature  : 
Place : Name         : 
 
CONSENT OF INFORMANT  
I have been informed to my satisfaction, by the attending physician, the purpose of 
the clinical trial, and the nature of drug treatment and follow up including the 
laboratory investigations to be performed to monitor and safeguard my Son / 
Daughter body functions.    
I am aware of my right to opt out to tail at any time during the course of the trial 
without having to give the reasons for doing so. 
        I am exercising my free power of choice, here by give my consent to be 
included as a subject in the clinical trial of “ VettumaranKuligai” for the treatment 
of Suram. 
 
Date   :  Informant Signature   :  
Place  :  Patient Name             :  
Signature of 
witness 
: 
 Informant Name  :  
Relationship  :  
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GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
PG DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PROFORMA OF CASE SHEET FOR SURAM 
 
 
IP. No. :  Religion :  
Bed No. :  Parents occupation :  
Name  :  Income :  
Age  :  Date of admission :  
Sex :  Date of discharge :  
Address  :  Diagnosis  :  
Informant :  Medical officer  :  
      
      
1. Complaints and duration  :  
2. History of present illness :  
3. History of past illness  :  
4. Antenatal history  :  
5. Birth history  :  
6. Neonatal history  :  
7. Developmental history  :  
8. Nutritional history   :  
9. Immunization history  :  
10. Family history :  
11. Allergy and contact history  :  
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12. Socio economic status :  
GENERAL EXAMINATION 
1. Level of consciousness  :  
2. Nutritional status  :  
3. Posture / Attitude  :  
4. Dysmorphic features  :  
5. Signs and respiratory distress :  
6. Anemia :  
7. Cyanosis  :  
8. Jaundice  :  
9. Clubbing :  
10. Koilonychias :  
11. Lymphadenopathy  :  
Anthropometry    
1. Height  :  
2. Weight :  
3. Head circumstances  :  
4. Mid arm circumstance  :  
Vital sign    
1. Temperature  :  
2. Pulse rate :  
3. Respiratory rate  :  
4. Heart rate  :  
5. Blood pressure  :  
SIDDHA ASPECTS    
Nilam   
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1. Kurinnji :  
2. Mullai :  
3. Marutham :  
4. Neithal :  
5. Paalai :  
Paruvakaalam   
1. Kaar :  
2. Koothir :  
3. Munpani :  
4. Pinpani :  
5. Elavenil :  
6. Muthuvenil :  
Poripulangal   
1. Mei  :  
2. Vaai :  
3. Kan :  
4. Mooku :  
5. Sevi :  
Kanmenthiriyam   
1. Kai  :  
2. Kaal :  
3. Vaai :  
4. Eruvai :  
5. Karuvai :  
Uyirthathukkal   
Vadham   
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1. Praaanan :  
2. Abaanan :  
3. Viyaanan :  
4. Uthaanan :  
5. Samaanan :  
6. Naagan :  
7. Koorman :  
8. Kirukaran :  
9. Devathathan :  
10. Dhananjeyan :  
Pitham   
1. Analpitham :  
2. Ranjagam :  
3. Saadhagam :  
4. Praasagam :  
5. Aalossagam :  
Kabam   
1. Avalambagam :  
2. Kilethagam :  
3. Pothagam :  
4. Tharpagam :  
5. Santhigam :  
UdalKattugal   
1. Saaram :  
2. Senneer :  
3. Oonn :  
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4. Kozhuppu :  
5. Enbu :  
6. Moolai :  
7. Sukkilam / Suronitham :  
Envagaithervugal   
1. Naadi :  
2. Sparisam :  
3. Naa :  
4. Niram :  
5. Mozhi :  
6. Vizhi :  
7. Malam :  
8. Moothiram :  
MODERN ASPECTS    
Respiratory system    
1. Inspection  :  
2. Palpation  :  
3. Percussion  :  
4. Auscultation  :  
 
Examination of other system     
1. Cardiovascular system :  
2. Gastrointestinal system :  
3. Central nervous system  :  
4. Excretory system  :  
5. Musculoskeletal system   
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Laboratory investigation      
Blood       
1. TC :  
2. DC :  
3. ESR (1 hr) :  
4. Hb % :  
Urine       
1. Albumin  :  
2. Sugar  :  
3. Deposits  :  
Stools    
1. Ova  :  
2. Cyst  :  
Others    
1. X ray chest  :  
2. Other investigation  :  
3. Summary of the case :  
4. Differential diagnosis  :  
5. diagnosis :  
6. Treatment  :  
7. Prognosis  :  
8. Prevention  :  
 
  
144 
 
GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI 
PG DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
ADMISSION DISCHARGE CASE SHEET 
 
 
IP. No. :  Religion :  
Bed No. :  Parents occupation :  
Name  :  Income :  
Age  :  Date of admission :  
Sex :  Date of discharge :  
Address  :  Diagnosis  :  
Informant :  Medical officer  :  
      
      
S.No. 
Clinical features 
(Signs and symptoms) 
During 
admission 
During discharge 
1.    
2.    
3.    
4.    
5.    
6.    
7.    
8.    
9.    
10.    
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